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EPM1 is a rare progressive neurode-
generative disorder with no specific 
cure. Mutations in the CSTB gene are 
responsible for the primary defect in 
EPM1. The study revealed that EPM1 
patients exhibit thickening of the 
skull and various bone abnormalities 
that link the CSTB mutation to bone 
metabolism. In visual assessment of 
MR images, focal brain abnormalities 
were not found but cortical thickness 
analysis (CTH) and texture analysis 
(TA) revealed subtle brain changes 
in patients with EPM1
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ABSTRACT 
 
Unverricht–Lundborg disease (EPM1) is the most common type of progressive myoclonic epilepsy clustered 
in Finland. It is caused by mutations in Cystatin B gene (CSTB) which is known to have role in 
neuroprotection and bone resorption. However, the exact pathogenesis of EPM1 and the role of CSTB in 
human function remain unknown. Despite the mutual genotype, the severity of the symptoms in EPM1 is 
heterogeneous. The main manifestations are observable in childhood or adolescence, which includes tonic–
clonic epileptic seizures and progressively increasing stimulus-sensitive myoclonic jerks. An estimated one-
third of the patients eventually become wheelchair-bound. 
This study is a part of Finnish EPM1 clinical and molecular genetics consortium research. The main aim 
was to further deepen the understanding of the radiological findings of EPM1 and to connect these findings 
to the EPM1 patients’ clinical phenotype. Altogether, 73 patients with EPM1 underwent 1.5 T head MR 
imaging in Kuopio University hospital during the period 2006–2010. MR images of the brain were examined 
by using the modern MR image analysis methods, cortical thickness analysis and texture analysis. 
Furthermore, the skeletal abnormalities of EPM1 patients were evaluated by quantitating calvarial MR 
findings and interpreting the x-rays and computed tomography studies collected from the medical records 
of the Finnish health institutions. 
The results show that EPM1 patients exhibit thickening of the skull and various bone abnormalities that 
link the CSTB mutation to bone metabolism. In visual assessment of MR images, focal brain abnormalities 
were not found but cortical thickness analysis and texture analysis revealed subtle brain changes in patients 
with EPM1. The patients with the severe form of disorder exhibit regional thinning of the cerebral cortex, 
including areas involved in higher-order cognitive functions providing anatomical-biological background 
for cognitive variation in EPM1. Texture analysis revealed textural changes in thalamus and right putamen 
compared to the healthy controls supporting the thalamic and putaminal involvement in the 
pathophysiology of EPM1. 
In conclusion, this study provides new and updated information on EPM1 patients’ skeletal 
characteristics. Modern MR Image analysis methods provide new data from visually normal brain MR 
images that gave also new insights for the pathogenesis of EPM1.  
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TIIVISTELMÄ 
 
Unverricht-Lundborgin tauti (EPM1) on yleisin progressiivisen myoklonisen epilepsian muoto, ja sitä 
tavataan eniten maailmassa Suomessa. Taudin syynä ovat CSTB-geenin virheet, joilla tiedetään olevan 
merkitystä hermokudoksen suojauksessa ja luun metaboliassa, mutta EPM1:n tautipatogeneesi ja CSTB:n 
tarkka rooli ihmiselimistössä ovat vielä selvittämättä. Huolimatta yhteisestä genotyypistä, taudin oireiden 
vaikeus on vaihtelevaa. EPM1:n pääpiirteisiin kuuluvat lapsuus- tai nuoruusiässä puhkeava oireisto, 
epileptiset tajuttomuuskouristuskohtaukset sekä vähitellen pahenevat ärsykeherkät lihasnykäykset, joiden 
seurauksena noin kolmannes potilaista joutuu pyörätuoliin. 
Tämä tutkimus on osa suomalaista, kliinistä ja molekyyligeneettistä EPM1-tutkimusta. Tutkimuksen 
tarkoituksena oli syventää sitä, mitkä EPM1:n radiologiset piirteet vaikuttivat sairauden vaikeusasteeseen. 
Kaiken kaikkiaan 73 potilaalle tehtiin aivojen 1.5 T magneettikuvaus Kuopion yliopistollisessa sairaalassa 
2006–2010. Magneettikuvat jatkoanalysoitiin moderneilla magneettikuva-analyysimenetelmillä, korteksin 
paksuusanalyysillä sekä tekstuurianalyysillä. Lisäksi potilaiden luuston poikkeavuuksia tutkittiin 
suomalaisista terveydenhuollon yksiköistä kerätyistä natiiviröntgen- ja tietokonetomografiatutkimusta sekä 
mittaamalla kallon luuston paksuutta magneettikuvista. 
Tulokset osoittavat, että EPM1-potilailla on kallon luuston paksuuntumista sekä erilaisia luustolöydöksiä, 
mikä liittää CSTB-mutaation luustometaboliaan. Visuaalisessa tarkastelussa pään magneettikuvista ei 
löytynyt fokaalimuutoksia, mutta korteksin paksuusanalyysi ja tekstuurianalyysi paljastivat vähäisiä 
aivomuutoksia EPM1-potilailta. Vaikeaa tautimuotoa sairastavilla potilailla oli merkittävästi ohuempi 
aivokuori muun muassa alueilla, jotka osallistuvat korkeampiin kognitiivisiin toimintoihin, mikä tarjoaa 
anatomis-biologista taustaa EPM1-potilailla havaittavaan vaihteluun kognitiivissa toiminnoissa. 
Tekstuurianalyysi paljasti potilailta teksturaalisia eroavaisuuksia talamuksessa ja putamenissa terveisiin 
verrokkeihin verrattaessa, mikä tukee talamuksen ja putamenin osuutta EPM1:n patofysiologiassa. 
Yhteenvetona, tämä tutkimus tarjoaa uutta tietoa EPM1-potilaiden luuston ominaisuuksista. Modernit 
magneettikuva-analyysimenetelmät tuovat uutta tietoa visuaalisesti normaaleista aivojen magneettikuvista, 
ja tutkimustulokset lisäävät myös ymmärrystä EPM1:n patogeneesistä. 
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1 Introduction  
Unverricht–Lundborg disease, also known as progressive myoclonic epilepsy type 1 
(ULD, EPM1, OMIM254800) is an autosomal-recessively inherited rare neurodegenerative 
disorder that belongs to the Finnish disease heritage with the highest incidence in the 
world (1:20 000) in Finland (Norio, Koskiniemi 1979, Kestilä, Ikonen & Lehesjoki 2010). It 
was first described by Unverricht 1891 in Estonia and Lundborg 1901 in Sweden, and it is 
still more common in Baltic Sea area as well as in Mediterranean areas until the present 
times. Sporadic cases are reported worldwide. (Kälviäinen et al. 2008) 
EPM1 is caused by the loss-of-function mutations in Cystatin B gene (CSTB) found 
partly by the Finnish researchers in 90’s (Lehesjoki et al. 1991, Pennacchio et al. 1996). 
Because of the neurodegenerative nature of EPM1 it can be concluded that the Cystatin B 
protein (CSTB) has a neuroprotective role. This has been proven in several molecular 
genetics studies. CSTB is also involved in bone resorption by inhibiting cathepsin K which 
is the main proteolytic enzyme in human osteoclasts (Laitala-Leinonen et al. 2006). 
However, the exact pathogenesis of EPM1 and the fundamental role of CSTB in human 
physiology remain unknown. 
The onset age of EPM1 is 6–16 years, before that the child develops normally. The 
most typical and first symptoms are tonic–clonic epileptic seizures and stimulus-sensitive 
myoclonic jerks. Initially, findings in neurological examination can be obscure but within 
the next 5–10 years motor symptoms slowly progress. Eventually, diagnosis is based on 
typical EEG finding, clinical examination and gene characterisation. Tonic-clonic seizures 
are usually well controlled with anti-epileptic drugs (AEDs). The disease is slowly 
progressive and the severity of symptoms ranges from mild motor difficulties in some of 
the patients to severe incapacitation in one third of the patients. (Kälviäinen et al. 2008) 
Imaging studies of EPM1 are sparse because of the rarity of the disorder. One of the 
original studies from the 70’s reports thickening of the skull and scoliosis in some patients 
with progressive myoclonic epilepsy (Koskiniemi et al. 1974) but systematic assessment of 
bony structures in EPM has not been performed to date. It is interesting that despite the 
progressive neurological symptoms, the neuroradiological findings in visual assessment of 
EPM1 brain remain sparse. There can be widespread mild to moderate cerebral and 
cerebellar atrophy but usually no focal signal changes of the brain are seen in patients with 
EPM1. However, the first radiological group analysis of patients with EPM1 performed by 
voxel-based morphometry (VBM) indicated motor cortex and thalamic atrophy that 
correlated with the degree of severity in myoclonus (Koskenkorva et al. 2009). 
This work continues the previous radiological research on EPM1 being a part of 
Finnish clinical and molecular genetic consortium study conducted by the Kuopio 
Epilepsy Center at Kuopio University Hospital and Folkhälsan Institute of Genetics at the 
University of Helsinki.  This doctoral thesis is focused to further investigate radiological 
findings of patients with EPM1 and to combine the radiological findings with patients’ 
clinical data and neuropsychological findings. The skeletal structures of EPM1 patients 
were systematically assessed from head MR images, x-rays and computed tomography 
studies. Brain structures were evaluated by using modern MR image analysis methods; 
cortical thickness analysis (CTH) and texture analysis. Recently, CTH analysis has been 
applied in brain research both to better understand human brain function and to 
characterize structural changes in various neurodegenerative disorders. Texture analysis is 
  
 
an old method first invented for satellite image analysis. It collapsed into oblivion but has 
experienced new coming in the field of medical imaging and so far, has not been applied 
widely in clinical research. 
3 
 
 
2 Review of literature 
2.1 UNVERRICHT–LUNDBORG DISEASE (EPM1) 
2.1.1 Overview of EPM1 and other progressive myoclonic epilepsies 
Progressive myoclonic epilepsies (PMEs) comprise a heterogeneous group of rare 
neurodegenerative disorders, characterized by myoclonus, epileptic seizures and 
progressive neurological impairment. PMEs are categorized into six disease groups: 
Unverricht–Lundborg disease (ULD, EPM1), Lafora disease (LD, EPM2), Neuronal Ceroid 
Lipofuscinoses (NCLs), sialidosis, Myoclonic Epilepsy of Ragged-Red Fibres (MERRF) and 
Dentatorubral–pallidoluysian atrophy. Disease progression and genetic aetiology are 
common features to all PMEs. They are usually inherited in autosomal recessive manner, 
and the genetic defects for PMEs have been identified (Table 1). MERRF makes an 
exception with maternal/mitochondrial inheritance. (Shahwan, Farrell & Delanty 2005) 
Due to rarity of the disorders research is challenging; in other words pathogenesis and the 
specific cure for various PMEs remains to be investigated.  
Main characters of PMEs are presented in Table 1. NCLs comprise a group of 14 
progressive encephalopathies where altogether five types are associated with PME 
(Shahwan, Farrell & Delanty 2005, Haltia, Goebel 2012). The onset age of PMEs is usually 
in childhood as in infantile forms of NCLs, or in puberty like in Lafora disease or EPM1, 
whereas MERRF and DRPLA can erupt at any age. Clinical manifestations of PMEs are 
varying. Usually ataxia, dysarthria and incoordination occur, in Lafora disease in early 
teenage years whereas in EPM1 an older age. Also the prognoses of various PMEs are 
variable with early cognitive decline and progressive dementia in Lafora disease leading 
to death at an early age whereas no premature death is seen in EPM1. Most of the PMEs 
are very rare occurring only in certain geographical spots like DRPLA that is rarely seen 
outside Japan. (Shahwan, Farrell & Delanty 2005) Furthermore, not only EPM1 but also 
CLN1, CLN3, CLN5, CLN8 have a background in Finnish disease heritage (Kestilä, Ikonen 
& Lehesjoki 2010). 
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2.1.2 Unverricht–Lundborg disease 
Unverricht–Lundborg disease or progressive myoclonic epilepsy type 1 (EPM1, ULD, 
OMIM254800) is the most common type of PME. It is clustered in Finland with a 
prevalence of 4:100 000 people and an incidence of 1:20 000 births per year (Norio, 
Koskiniemi 1979, Kälviäinen et al. 2008). EPM1 is also more common in Baltic Sea and 
Western Mediterranean regions. Sporadic cases of EPM1 are reported worldwide, and it 
has been suggested that EPM1 is underdiagnosed. (Kälviäinen et al. 2008, Eldridge et al. 
1983, Moulard et al. 2002, de Haan et al. 2004) The genetic background of EPM1 was 
identified 20 years ago to localise in chromosome 21q22.3 and it is caused by the loss of 
function mutations in Cystatin B encoding CSTB gene (Lehesjoki et al. 1991, Pennacchio et 
al. 1996). 
2.1.2.1 Clinical characteristics 
Before the manifestation of EPM1, child’s cognitive and physical development is usually 
normal. The age of onset is 6–16 years peak being around the 12–13 years and the first 
symptoms are tonic–clonic epileptic seizures and stimulus-sensitive and action-activated 
myoclonic jerks (Kälviäinen et al. 2008, Genton 2010). 
Myoclonus denotes sudden, involuntary twitching of muscles without any rhythmical 
pattern and it can be classified according to the aetiology, clinical signs or anatomic origin 
of myoclonic jerks (Dijk, Tijssen 2010). In EPM1, asynchronous focal or multifocal positive 
muscular contractions occur mainly in the proximal muscles of the extremities. They can 
be action-activated or stimulus sensitive, provoked generally by light, but also any other 
stimuli like stress, noise and physical exertion. On occasion, myoclonus proceeds into 
serious continuous myoclonic jerks i.e. status myoclonicus with inability to respond and; a 
situation, which may be difficult to differentiate from a generalized epileptic seizure. 
Anatomic origin of myoclonus in EPM1 is considered to be cortical but evidence of 
multilevel origins exist as well (Kälviäinen et al. 2008). Myoclonus, is the first symptom in 
over a half of the affected individuals, and the most disabling symptom affecting the daily 
life of a patient with EPM1 (Koskiniemi et al. 1974). 
Separate from myoclonus, the seizure type seen in EPM1 is almost exclusively 
generalized tonic–clonic seizure (Norio, Koskiniemi 1979, Koskiniemi et al. 1974). Few 
video-EEGs of absence, simple motor or complex focal seizures have been documented 
but they might be just poorly diagnosed seizures of myoclonic origin. On rare occasions, 
tonic–clonic seizures are not present. (Kälviäinen et al. 2008) 
In the following years after the onset of EPM1, symptoms will slowly progress. 
Nonetheless, in some cases of EPM1, the symptoms are so mild that it can lead to a delay 
of the diagnosis. In addition, there is variation in the speed of progression and severity of 
symptoms among the patients with EPM1. An individual patient’s symptoms may 
fluctuate in terms of good days and bad days for years. (Kälviäinen et al. 2008) Myoclonus 
progresses within 5–10 years reaching a plateau, and motor symptoms including 
dysarthria, ataxia, intention tremor and incoordination, will develop. One third of the 
patients lose their ability to walk and handle the daily routine which leads to severe 
incapability and makes the patients wheel-chair bound, in some of the cases as early as in 
the twenties. Furthermore, based on the longitudal study of 20 years it has been suggested 
that EPM1 would progress only in a limited period (Magaudda et al. 2006). At the onset, 
seizures are occasional increasing in frequency during the following 3–7 years while at the 
later stages of the disorder, seizures may cease entirely with a suitable medication 
(Kälviäinen et al. 2008). The cause of the variation in the severity of the phenotype of 
EPM1 remains unknown. However, the most recent studies have shown that the 
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compound heterozygous patients exhibit a more severe form of disorder than the 
homozygous patients (Koskenkorva et al. 2011, Canafoglia et al. 2012). 
2.1.2.2 Prognosis 
Compared to the other PMEs, EPM1 has a relatively good prognosis (Shahwan, Farrell & 
Delanty 2005). As late as the 1970’s, patients spent the last years of their life bed-bound 
and died on average under age of 30 years (Koskiniemi et al. 1974). This was supported by 
the use of an established AED phenytoin, which seemed to aggravate the associated 
neurologic symptoms or even accelerate the cerebellar degeneration in EPM1 (Eldridge et 
al. 1983, Iivanainen, Himberg 1982). When phenytoin was abandoned, both the life 
expectancy and the quality of life in EPM1 increased. The oldest genetically verified 
Finnish patients with EPM1 have lived into their seventies, and premature deaths due to 
pneumonia or suicide are seen more seldomly in EPM1 currently. (Kälviäinen et al. 2008, 
Shahwan, Farrell & Delanty 2005) However, unexpected deaths (SUDEP, sudden 
unexpected death in epilepsy) are reported also in EPM1 (Khiari et al. 2009). 
2.1.2.3 Diagnosis 
Diagnosis of EPM1 is based on typical clinical findings in a previously healthy child or 
adolescent between 6–16 years (Table 2). In neurological examination, the clinical findings 
may be initially sparse. However, imperceptible myoclonus provoked by a stimuli (photic: 
bright light; sudden loud noise) or an action (clapping of the hand, testing the reflexes) can 
be noted. Later myoclonus becomes more evident, though it should be noted that the 
patient has not taken additional benzodiazepam or alcohol before the examination, which 
can dispel the real symptoms. 
 
Table 2. Diagnosis of EPM1 modified from Kälviäinen et al. 2008. 
A) Previously healthy child with onset age of 6–16 years 
B) Two of the following symptoms or findings 
1) Myoclonus Involuntary: stimulus-sensitive or action-activated 
2) Seizure Generalized tonic–clonic 
3) Motor dysfunction Mild difficulties in gross motor functions or coordination 
4) EEG Marked photosensitive, generalized spike-and wave and polyspike and 
wave paroxysm in EEG. The EEG background activity varies from normal 
to mildly slowed and remains stable over time 
5) MRI Normal or signs of cortical or central atrophy, no focal pathology 
6) Progression Gradual progression of the symptoms, ataxia and myoclonus 
C)      Gene test 
 
MRI is performed for the differential diagnostic purposes to verify seizure aetiology 
while at the time of the diagnosis, almost without exception, the brain MR image finding 
of a patient with EPM1 is normal (Kälviäinen et al. 2008). 
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The characteristic findings from an EEG may already be observed at the onset of EPM1 
being more pronounced at the initial stages of the disorder. The typical findings include a 
normal or moderately slow background activity, and generalized fast spike or polyspike 
and wave discharges (Koskiniemi, Toivakka & Donner 1974, Ferlazzo et al. 2007). The 
discharges are provoked typically by photic stimulation, but they can also be provoked by 
other stimulus, or spontaneously. Also evidence of focal epileptiform EEG changes mainly 
from the occipital region have been observed (Kälviäinen et al. 2008). Similarly to the 
stabilization of tonic–clonic seizures, EEG changes may reduce over time while the 
background activity remains stable (Ferlazzo et al. 2007). 
Eventually, genetic testing confirms the diagnosis of EPM1 (Kälviäinen et al. 2008). 
Gene testing should be performed, when there is considerable reason to suspect the 
diagnosis of EPM1 (symptomatic cases), not as screening test. 
The main consideration in the differential diagnosis of EPM1 is juvenile myoclonic 
epilepsy (JME). JME is a relatively common form of genetic generalized epilepsy 
representing 10 % of all epilepsies (Kälviäinen 2007). It shares several resemblances with 
EPM1 including onset at 12–18 years, tonic–clonic seizures, occasional myoclonic jerks and 
similar epileptiform EEG findings. JME has a more benign outcome, so initially the mild 
cases of EPM1 can be misdiagnosed as JME. In JME neurological examination is, however 
always normal and myoclonic jerks do not interfere with daily functions. Eventually, other 
PMEs should be suspected in an affected individual if the symptoms are severe and 
progress more quickly than expected. 
2.1.2.4 Treatment 
Similar to other PMEs, there is currently no specific cure for EPM1 and the treatment 
remains palliative consisting of combination of symptomatic AEDs and antimyoclonic 
drugs, lifelong rehabilitation and comprehensive psychosocial support (Kälviäinen et al. 
2008). Medication is a challenge, even if the majority of various AED’s have a good 
response to convulsive seizures the response for the most disabling symptom in EPM1, 
myoclonus, stands poor. However, valproate is a drug of choice for seizures and 
myoclonus control, and it can be used as a monotherapy in mild cases (Norio, Koskiniemi 
1979, Kälviäinen et al. 2008, Iivanainen, Himberg 1982). Normally, a more effective 
therapy is needed and valproate is added with clonazepam or newer drugs, piracetam, 
topimarate and levetiracetam (Kälviäinen et al. 2008, Shahwan, Farrell & Delanty 2005, 
Iivanainen, Himberg 1982). A recent single center study showed that polytherapy with 
valproate was in use by all patients with EPM1. Improvement in myoclonia was recorded 
for the majority of patients with either add-on piracetam, topiramate, or levetiracetam but 
add-on AED treatment was also often associated with significant adverse effects 
(Roivainen, Karvonen & Puumala 2014). It should be noted that there is a spectrum of 
other AED’s (for example phenytoin, carbamazepine, oxcarbazepine, pregabalin), which 
can increase the symptoms of EPM1 and should be avoided (Kälviäinen et al. 2008, 
Shahwan, Farrell & Delanty 2005). In acute cases of generalized status myoclonus 
benzodiazepines, valproate and levetiracetam are used intravenously (Kälviäinen et al. 
2008). 
Based on suggested deficit in dopaminergic inhibitory neurotransmission, dopamine 
D2-receptor agonist ropinirole seemed to diminish motorical symptoms as an 
experimental add-on treatment in a case study of one patient (Mervaala et al. 1990, 
Karvonen et al. 2010). Third-generation AED brivaracetam has shown promising results in 
preliminary studies and is under investigation for treatment of myoclonus (Kälviäinen et 
al. 2008, Tai, Truong 2005). 
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2.1.3 Neuropsychological studies in EPM1 
There are few studies of cognitive function in EPM1 found in literature. The first study by 
Koskiniemi et al. evaluated a population of 93 patients with stimulus-sensitive myoclonus, 
epileptic seizures, onset age 5–16 years, characteristic EEG and progressive course 
(Koskiniemi et al. 1974) that can now be considered as EPM1. They found that full scale 
Intelligence Quotient (FIQ) scores were variable alternating from 55 to 129. A negative 
correlation between age and FIQ was found. 
Previously, it has been stated that the intellectual functioning in EPM1 is normal in 
most of the patients but mild to moderate intellectual dysfunction or mild dementia in 
single patients with EPM1 have also been reported (Magaudda et al. 2006, Mazarib et al. 
2001, Chew et al. 2008). However, neuropsychological assessment of 20 patients with 
EPM1 revealed broad variability in cognitive functioning ranging from normal to 
moderately impaired where the mean of FIQ was 68. Attention and short-term memory 
were identified the main functions impaired but long-term memory, visual perception and 
visuospatial reasoning remained as less impaired cognitive domains. On the contrary to 
the Koskiniemi et al., no significant correlation was found between the duration of the 
disorder and FIQ scores (Ferlazzo et al. 2009). Furthermore, comparison between patients 
with EPM1 and patients with cryptogenic temporal lobe epilepsy or healthy controls 
found that particularly processing and executive functions were impaired in EPM1 
(Giovagnoli et al. 2009). 
Psychiatric disorders have not been widely investigated in EPM1. Mental disturbances 
are reported in individual patients with EPM1 including depression, anxiety, 
aggressiveness and mood lability. Particularly depression has been observed (Magaudda 
et al. 2006, Chew et al. 2008, Ferlazzo et al. 2009) and studies have also reported suicides 
following severe depression (Koskiniemi et al. 1974, Khiari et al. 2009). 
 
2.1.4 Previous imaging studies of EPM1  
2.1.4.1 Skeletal involvement in EPM1 
Extracerebral imaging studies in EPM1 are sparse. As early as in 1970’s Koskiniemi et al. 
reported thickening of the skull and thoracic scoliosis (Koskiniemi et al. 1974) from a series 
of 31 patients. Later Korja et al. reported hyperostosis frontalis interna -type of skull 
thickening from the head MRI of four EPM1 patients (Korja et al. 2007a). Thickening of the 
skull has also been reported in a case report of a patient with two different mutations, both 
EPM1 and myotonic dystrophy, who had a thick bony structure of the skull in MRI but  no 
focal pathologic changes in the brain parenchyma were observed (Nokelainen et al. 2000). 
 
2.1.4.2 Imaging of the brain in EPM1 
Studies concentrating on radiological evaluation in EPM1 are still scanty (Table 3). Most of 
the EPM1 imaging studies list individual patients’ findings rather than are based on group 
analysis.  
In direct visual inspection of the brain, findings remain scarce in patients with EPM1. In 
CT or MR images, generalized brain atrophy or mild to moderate atrophic changes both in 
cerebrum and cerebellum have been reported in individual patients (Koskenkorva et al. 
2009, Chew et al. 2008, Giovagnoli et al. 2009, Parmeggiani et al. 1997, Mascalchi et al. 
2002, Korja et al. 2007b, Santoshkumar, Turnbull & Minassian 2008). Focal changes in the 
brain parenchyma are not commonly found in patients with EPM1. White matter lesions 
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are reported in 2 of 8 patients in a study describing the clinical characteristics of EPM1 
(Chew et al. 2008). White matter changes were found in 8 patients from a total of 13 
patients compared to the healthy controls and long-term epilepsy patients. Five of patients 
with EPM1 had T2-weighted high-intensity signal changes in basal ganglia especially in 
the right (Korja et al. 2010). However, most of the studies in patients with EPM1 report no 
focal changes in the brain parenchyma (Nokelainen et al. 2000, Mascalchi et al. 2002, 
Koskenkorva et al. 2012).  
More recently, modern MR image analysis methods have been able to detect more 
specific changes in brain of EPM1 patients. A MRI-based morphometry evaluation of 10 
homozygous patients with EPM1 has represented loss of neuronal volume in the 
brainstem; basis pontis, medulla and cerebellar hemispheres, whereas significant changes 
were not found in vermis, middle cerebellar peduncule and fourth ventricle compared to 
the controls (Mascalchi et al. 2002). The study also obtained magnetic resonance 
spectroscopy (MRS) of the pons and dentate, and showed significantly reduced N-
acetylaspartate/creatine (NAA/Cr) and choline/creatine (Cho/Cr) ratios in the pons 
(Mascalchi et al. 2002). Another study with MRS has reported that the lactate 
concentration was increased in the cerebrospinal fluid (CSF) in one compound 
heterozygous patient (Koskenkorva et al. 2011). 
Voxel-based morphometry (VBM) has shown loss of grey matter volume bilaterally in 
motor cortex, cuneus and thalami in patients with EPM1 compared to the healthy controls 
(Koskenkorva et al. 2009). Also, the right cuneus and left lateral orbital gyrus were 
involved. There was no difference in grey matter volume between the patients with 
shorter and longer duration of the disease. Furthermore, patients with EPM1 showed 
widespread cortical thinning compared to the healthy controls in cortical thickness 
analysis study (Koskenkorva et al. 2012). The affected areas included sensorimotor, visual 
and auditory cortices. The age-related thinning of the cortex was diffuse in healthy 
controls whereas in patients with EPM1 the thinning was confined to more limited areas, 
and also the duration of disease was negatively correlated with cortical thinning in same 
regions as the age effects in patients with EPM1. There was also a significant negative 
correlation between the scores measuring the severity of myoclonus (Myoclonus with 
Action score) and cortical thickness in patients with EPM1. In other words, the areas of 
regionally reduced cortical thickness were parallel with the severity of the action 
myoclonus symptoms. 
Translational study in patients with EPM1 and Cstb–/–  mice showed widespread changes 
in white matter resulting in axonal degeneration and white matter loss (Manninen et al. 
2013). WM changes were especially seen in subcortical WM, thalamocortical system and 
cerebellum. The study provided new aspects of motor disability in EPM1 relating not only 
to the cortical changes but also deeper WM structures. 
Finally, higher binding potential of the D2-like receptor antagonist ([11C]raclopride) in 
the  thalamus, nucleus caudatus and putamen have been reported in a PET study of four 
patients with EPM1 compared to the healthy controls suggesting a dopamine depletion in 
the thalamostriatal area in EPM1 (Korja et al. 2007b). 
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2.1.5 Genetics and molecular basis of EPM1 
2.1.5.1 Etiology of EPM1 
EPM1 is caused by the mutations of the Cystatin B protein encoding CSTB gene 
(Pennacchio et al. 1996, Lalioti et al. 1997, Lafreniere et al. 1997) that result in substantially 
reduced CSTB gene and protein expression. EPM1 is inherited in autosomal recessive 
manner (Pennacchio et al. 1996) and the majority of EPM1 cases are homozygous for the 
expanded dodecamer repeat mutation in the promoter region of the CSTB gene (Virtaneva 
et al. 1997). However, some EPM1 patients are compound heterozygous for the dodecamer 
repeat expansion and the c.202C>T mutations with five known cases in Finland (Joensuu, 
Lehesjoki & Kopra 2008). So far, 14 loss of function mutations in the CSTB gene have been 
identified (Tegelberg 2013). 
A few patients with a phenotype similar to EPM1 have mutations in the PRICKLE1, 
SCARB2 or GOSR2 genes (Bassuk et al. 2008, Corbett et al. 2011, Dibbens et al. 2009). Also, 
a new clinical phenotype resembling EPM1 has been reported where the CSTB mutation is 
not seen and the exact mutation is under investigation (Berkovic et al. 2005). 
 
2.1.5.2 Cstb-deficient mouse model for EPM1 
Cstb-knockout mouse model (Cstb–/–) where the CSTB gene is inactivated causes a 
phenotype that recapitulates the key clinical features of EPM1 (Pennacchio et al. 1998). 
Cstb–/–  mice show sufficiently the main aspects of EPM1 including myoclonic seizures and 
progressive ataxia but no tonic–clonic seizures or photoconvulsive response are seen. 
Initially, mouse model revealed apoptotic loss of cerebellar granule neurons whereas the 
signs of the apoptosis were sparse in the other parts of the brain (Pennacchio et al. 1998). 
Later studies have shown early microglia activation even in clinically normal young Cstb–/–  
mice and widespread gliosis followed by intense astrocytosis and progressive neuron loss 
in the cerebral cortex, cerebellum, thalamus and thalamocortical system (Shannon et al. 
2002, Franceschetti et al. 2007, Tegelberg et al. 2012). Recently, a diffusion tensor imaging 
study reported that the diffusion changes in the white matter are similar in patients with 
EPM1 to those in cstb-deficient mice with the most remarkable changes found in the 
pyramidal tracts, thalamus and cerebellum (Manninen et al. 2013). Another recent study 
revealed early WM alterations in all major tracts and progressive non-uniform volume loss 
in the brain of cstb-deficient mice while brain volume increased in the control mice group 
(Manninen et al. 2014). 
The pathological changes in hippocampus have remained controversial in literature of 
EPM1. Shannon et al reported massive apoptosis and gliosis within the hippocampal 
formation and entorhinal cortex whereas later stage mice had no activated microglia in 
hippocampi in a study of Tegelberg et al. (Shannon et al. 2002, Tegelberg et al. 2012). 
However, it has also been hypothesized that hippocampus plays a crucial role in the 
pathophysiology of EPM1.  A significant loss of GABAergic interneurons has been found 
in the dorsal hippocampus associated to the more hyperexcitable hippocampi of Cstb–/–  
mice and higher susceptibility to seizures (Franceschetti et al. 2007). Macroscopically, the 
seizure-prone and seizure-resistant mice display similar neuropathologic changes 
(Pennacchio et al. 1998, Shannon et al. 2002). 
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2.1.5.3 CSTB, Cystatins and Cathepsins 
CSTB encodes Cystatin B protein which is an endogenous inhibitor of cysteine proteases, 
cathepsins (Järvinen, Rinne 1982, Green et al. 1984). Experimental work has shown a 
neuroprotective role of CSTB and the contribution of both Cystatin B and Cystatin C to the 
pathophysiology of EPM1 (Pennacchio et al. 1998, Shannon et al. 2002, Lieuallen et al. 
2001, Rinne et al. 2002, Houseweart et al. 2003, Lehtinen et al. 2009, Kaur et al. 2010).  
Cystatin B and Cystatin C are the members of cystatin superfamily. They are expressed 
ubiquitously in human cells and have diverse roles in human physiology and disease 
processes including inflammation, cancer and neurodegeneration (Keppler 2006). Both 
Cystatin B and C inhibit cathepsins B, H, L, and S (Kopitar-Jerala 2006), Cystatin B also 
inhibits cathepsin D and probably cathepsin K (Laitala-Leinonen et al. 2006, Kaur et al. 
2010, Yang et al. 2011). 
Loss of Cystatin B function leads to enhanced cytosolic activity of cathepsins in EPM1 
(Lieuallen et al. 2001, Rinne et al. 2002, Houseweart et al. 2003). Cstb-deficient mouse 
model for EPM1 showed that removal of cathepsin B from Cstb–/–  mice strongly improves 
the EPM1 phenotype whereas removal of cathepsins L or S did not cause any changes to 
the phenotype of Cstb–/–  mice (Houseweart et al. 2003).  
An in vitro study has shown that CSTB is involved in bone resorption by regulating the 
intracellular Cathepsin K activity (Laitala-Leinonen et al. 2006). Cathepsin K is a major 
cysteine protease and has a critical role in bone resorption (Gelb et al. 1996, Saftig et al. 
1998, Xia et al. 1999). In mice, overexpression of cathepsin K is related to enhanced 
osteoclastic bone resorption, osteopenia of metaphyseal trabecular bone, and increased 
cortical thickness and cortical bone mineral density in the diaphyseal regions (Kiviranta et 
al. 2001, Morko et al. 2005). 
The role of Cystatin C in EPM1 is not as widely investigated as Cystatin B. It has been 
shown that the expression of Cystatin C is enhanced in the brains of Cstb–/–  mice and the 
overexpression of Cystatin C rescues cerebral cortices and cerebellum from the cell death 
and gliosis (Kaur et al. 2010). In the light of present knowledge, Cystatin B and C and 
Cathepsin B, D and K have a contribution to the pathophysiology of EPM1. 
 
2.2 OVERVIEW OF SKELETAL VARIABILITY IN HEALTH AND DISEASE  
 
There are two types of bones based on the embryological origins: those with 
intramembranous ossification where the ossification takes place directly, and those with 
endochondral ossification with a cartilage precursor. The majority of the human bones, 
including long bones, vertebral column and skull base are developed through the 
endochondral ossification whereas the cranial vault (frontal bone, parietal bone, parts of 
temporal and occipital bones) and facial bones are developed via the intramembranous 
ossification. Although the embryology creates the basis for the skeleton, structural changes 
during the growth of the bone are an ongoing process. During the first year of life, almost 
the entire skeleton is replaced with continuum of 10 % remodelling per year. There are 
two major factors associated with bone remodelling, the osteoblasts and osteoclasts with 
various affecting factors both from genetic and environmental sources. Bone metabolism is 
a complicated and susceptible process varying from too effective bone resorption leading 
to osteoporosis, all the way to dysfunctional ossification that causes osteopetrosis. (Cohen 
2006) Thus, seemingly small factors can disrupt the balance of bone metabolism leading to 
the pathogenesis of various skeletal diseases. This has been also recognized during drug 
development processes, for example for osteoporosis, with unexpected side-effects 
(Rachner, Khosla & Hofbauer 2011). In the following sections, the skeletal abnormalities 
studied in this thesis are reviewed. 
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2.2.1 Skull 
The human skull, size, shape and cranial thickness have been investigated extensively. In 
recent history, by characterizing the morphology of the human skull, 
palaeanthropological, archeological, anthropological and other investigators have tried to 
explain human differences from behavioral and racial differences to intelligence. 
Intentions have not been always ethical (Greenblatt 1995). When it comes to human 
ancestors, subspecies of Homo sapiens, morphological differences of the skull are obvious. 
One topic for researchers has been to find correlations between cultural and sex 
differences and skull thickness. Early anthropological studies suggested that men have 
thicker skulls because of the size difference between men and women, but modern 
autopsy biopsy studies and one MRI study found no correlation between age, gender and 
body composition and thickness of the skull excluding hyperostosis frontalis interna (HFI) 
(Hershkovitz et al. 1999, Ross, Jantz & McCormick 1998, Hatipoglu et al. 2008). However, 
characteristics of the skull morphology are used to identify archeological findings, and 
recently, also modern radiological imaging methods are used to characterize calvarial and 
other skeletal structures of mummies (van Kaick, Delorme 2005). One of the characteristic 
skull findings is hyperostosis frontalis interna (HFI) (May et al. 2011).  
Hyperostosis frontalis interna is a symmetrical protrusion on the inner table of the 
frontal bone (Hershkovitz et al. 1999). HFI is a sex- and age-dependent phenomenon of 
unknown aetiology that is highly related to the hormonal changes that vary over a 
lifetime, especially prolonged estrogen stimulus during the fertility has been suggested to 
be the reason to the HFI seen in postmenopausal females (Hershkovitz et al. 1999, Ross, 
Jantz & McCormick 1998). The overall prevalence of HFI is 5–12%, but it is notably higher 
among post-menopausal elderly women (40–60%). When both CT and MR imaging have 
become more frequent and routine, HFI has become a general incidental finding that by 
itself does not cause significant clinical disease (Hershkovitz et al. 1999). Thus, according 
to the present knowledge, HFI can be considered a separate, non-disease-related 
phenomenon.  
Thickening of the skull is associated with many disorders, such as severe anaemia, 
polycythemia vera, myelofibrosis, hyperparathyroidism and myeloproliferative diseases 
such as lymphoma, multiple myeloma and myelodysplastic syndromes. (Ghanem et al. 
2006, Nobauer, Uffmann 2005) Paget's disease is a relatively common entity with skull 
thickening and other bone findings, occurring in middle age (3–4% of those >40 years of 
age) (Smith et al. 2002). 
In the 1970’s an established AED, phenytoin was commonly used to treat epilepsy in 
Finland. Generalized thickening of the skull has been shown to associate with the long-
term use of phenytoin (Kattan 1970). A more recent case report describes skull thickening 
and cerebral atrophy after thirteen years of phenytoin use (Chow, Szeto 2007). Finally, 
thickening of the skull has been reported in various inherited diseases that are reviewed in 
Table 9 (see page 50). 
In this study, the paranasal sinuses of the patients with EPM1 were also evaluated. 
Paranasal sinus pathology is familiar for every physician because of common sinuitis. 
Hypoplasia of paranasal sinuses is a frequently mentioned entity but not much can be 
found from the literature about large paranasal sinuses which can be usually noted in 
acromegaly (Burgener, Kormano & Pudas 2008). However, large frontal sinuses are 
observed in some rare syndromes like Dyke Davidoff-Masson syndrome which is a 
neurological disorder characterized by marked hemiatrophy or hypoplasia of one cerebral 
hemisphere, contralateral hemiparesis and epileptic seizures (Table 9) (Atalar, Icagasioglu 
& Tas 2007).  
15 
 
 
2.2.2 Spine 
Scoliosis, an abnormal curving of spine, is a common finding and a widely investigated 
spinal deformity: in a PubMed search it gives over 17000 hits. The literature reports 
prevalence rates for scoliosis that vary from 1% among school children to 8.3% among US 
adults aged 25–74 years and up to 35.5% among individuals older than 60 years (Carter, 
Haynes 1987, Hong et al. 2010, Ueno et al. 2011). It can be categorized into congenital, 
syndromatic or idiopathic. Abnormally formed vertebrae such as hemivertebrae, fused 
vertebrae and vertebral hypoplasia appearing early in development cause congenital 
scoliosis. Syndromatic or secondary scoliosis is associated with some other 
neuromuscular, skeletal or connective tissue disorder.  Examples for syndromatic and/or 
congenital scoliosis are also widespread in patients affected by the syndromes shown in 
Table 9. Eventually, the most common form of scoliosis is idiopathic scoliosis where the 
cause remains unknown. Idiopathic scoliosis can be divided by the age of onset to the 
infantile, juvenile and adolescent forms. (Altaf et al. 2013) Several other types of vertebral 
anomalies exist, see Burgener & Kormano (Burgener, Kormano & Pudas 2008). 
2.2.3 Other skeleton  
Accessory ossicles of the foot are a relatively common congenital skeletal finding in 
normal population and the knowledge of accessory ossicles is beneficial when diagnosing 
fractures of the foot (Burgener, Kormano & Pudas 2008). The most common accessory 
ossicles are os tibiale externum with the estimated prevalence of 4–21% in healthy 
individuals. Other accessory ossicles like os trigonum and os peroneum are less prevalent 
(Mellado et al. 2003). In rare cases, there can be coalitions in the bones of the foot for 
example talonavicular and talocalcaneal coalitions (Burgener, Kormano & Pudas 2008).  
Similar to the feet, many syndromes may also affect the hand. Arachnodactyly is seen in 
Marfan syndrome and it is defined when metacarpal index is more than 8. Metacarpal 
index is calculated by dividing the sum of the lengths by the sum of the widths of 
metacarpals II–V. In positive metacarpal sign the tangent of IV and V metacarpal heads 
passes through the head of the third metacarpal and it can be seen e.g. Turner’s syndrome 
(Burgener, Kormano & Pudas 2008). 
There are various other congenital anomalies in 206 bones of human skeleton including 
shortened and malformed limbs, absence of bones or part of them, and multiple 
deformities due the bone-connective-tissue-matrix problems (see Burgener et Kormano) 
but they are not included to the topic of this thesis. 
Bone mineral density (BMD) describes the amount of mineral matter per cubic 
centimeter (g/cm3) that can be examined by dual x-ray absorptiometry (DXA). Osteopenia 
is a condition where bone mineral density is lower than normal (BMD is 80–120 mg/cm3 
and T-score between -1.0 and -2.5). Osteoporosis means progressive bone disease where 
both bone mineral density and bone mass are decreased (BMD is < 80 mg/cm3 and T-score 
of less than -2.5). (Adams 2013) Several medical entities are related to the bone loss 
including endocrine diseases, rheumatoid artritis and other autoimmune disorders, 
cancers, malnutrition, smoking, excess use of glucocorticoids and chronic immobilization 
for example among the wheelchair users that increase the risk of osteoporotic fractures. 
(Rachner, Khosla & Hofbauer 2011) Osteoporosis is a problem in patients with chronic 
epilepsy and the association between low BMD and AEDs is strongly detected (Beerhorst 
et al. 2012). 
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2.3 BACKGROUND FOR STRUCTURAL BRAIN IMAGE ANALYSIS  
2.3.1 Anatomy of cerebral cortex 
Cerebral cortex is a crumpled and folded 6-sheet layer of grey matter forming numerous 
convolutions (gyrus) and crevices (sulcus) divided into right and left hemispheres and 
frontal, temporal, parietal and occipital lobes. With over 1010 neurons and various 
neurotransmitter connections to subcerebral areas e.g. thalamus and brainstem, cerebral 
cortex is a very complex structure that is largely responsible for higher brain functions e.g. 
memory, sensation and voluntary muscle movement. (Bear, Connor & Paradiso 2007)  
Division of cerebral cortex can be comprehend and named several ways with three 
introduced here (Table 4). Anatomically cerebral cortex is named based on its gyri and 
sulci, every gyrus and sulcus has its own anatomic name (Duvernoy 1999). Functionally, 
cerebral cortex is basically divided into motor, sensory and association areas and smaller 
sophisticated functions of these parts are used to classify and name cerebral cortex. (Bear, 
Connor & Paradiso 2007) Brodmann’s map from 1909 is a base of modern structural 
neuroimaging and understanding of function of human cerebral cortex (Zilles, Amunts 
2010). Korbian Brodmann described total of 43 different areas that are based on both 
anatomical and functional cytoarchitecture and this classification is still a functional way 
to understand the cerebral cortex for researchers, physicians and radiologists (Figure 1). 
During the embryogenesis cerebral cortex undergoes several developmental steps. This 
formation continues throughout the childhood and youth when finally at the age of 6–7 
years gray matter volume starts to decrease and vice versa white matter volumes increase. 
(Kolb, Whishaw 2009). It seems that, GM loss, also known as brain maturation, starts in 
phylogenetically older brain areas. In other words the lower-order cortices develop before 
higher-order association cortices (Gogtay et al. 2004). It is commonly known that during 
aging the cerebral cortex becomes thinner (Salat et al. 2004, Fjell et al. 2009a, Thambisetty 
et al. 2010, McGinnis et al. 2011). Furthermore, the thickness of the cortex varies regionally. 
Cortical differences have been found between men and women but it seems that in the 
aging brain the sex does not matter (Luders et al. 2006, Sowell et al. 2007, Fjell et al. 2009b). 
It is crucial to know the anatomy and function of cerebral cortex to understand the 
possible underlying disease mechanisms. Yet, associations between cortical formation, 
function and thinning are poorly understood. 
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Figure 1. Brodmann’s map illustrated in lateral and medial views. 
 
2.3.2 Cerebral cortex and neurocognition 
Cerebral cortex is a small part of a human brain, only 1.5–3.0 mm thick, and it is an 
essential for cognitive function. Humans and other intelligent species have larger brains 
and thicker cortices. Cerebral cortex contains areas that are involved in higher-order 
cognitive functions, a group of mental processes used for perception, processing and 
applying of new knowledge. (Kolb, Whishaw 2009) The basic aspects of cognition are 
same in human and other animals, many of cognitive functions like language, problem 
solving and learning, are the most developed in human being although the uniqueness of 
human brain has started to be to criticized (Herculano-Houzel 2012). Speech is a primary 
example of peculiar function of human cerebral cortex. Cognition and cerebral cortex have 
been widely investigated and debated with several theories on the organization of 
cognitive function.  
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2.3.3 Highlighted cortical areas involved in cognitive tasks 
Posterior section of frontal lobe is responsible for motor skills (Bear, Connor & Paradiso 
2007). In front of the primary motor cortex lies the premotor cortex that includes area BA6. 
Frontal eye fields (BA8) lie in or just before BA6 in the medial part of frontal lobe. BA8 
includes the areas that participate in the control of saccadic eye movements (Amiez, 
Petrides 2009). 
Anterior portion of frontal lobe comprises prefrontal cortex which retains the highest 
components of human behaviour (Kolb, Whishaw 2009). Dopamine plays an important 
role in the neurotransmission in prefrontal cortex and is involved in higher-order 
cognitive functions (Robbins, Arnsten 2009, Benchenane, Tiesinga & Battaglia 2011). In 
humans prefrontal cortex can be divided in ventrolateral, dorsolateral, orbitofrontal, 
ventromedial and frontopolar prefrontal cortex. 
Ventrolateral prefrontal cortex, VLPFC (BA, 44, 45 and 47) receives detailed information 
of objects from the visual pathways in conjunction with motivational and emotional 
knowledge from subcortical areas and orbitofrontal cortex that is together committed for 
decision making or design of goal-directed behaviour (Sakagami, Pan 2007). VLPFC is 
considered to have significantly differing roles in two brain hemispheres e.g. verbal 
stimuli leads to activation of left VLPFC whereas visuospatial stimuli leads to the 
activation of right VLPFC (Levy, Wagner 2011).  
Ventromedial prefrontal cortex (VMPFC) receiving signals from supplementary motor 
cortex, dorsal striatum and parts of parietal cortex, is also involved in goal-directed 
decision making and selection based on value of goals (O'Doherty 2011). VMPFC has been 
suggested to have an interesting role in emotional decision e.g. moral judgement between 
right and wrong (Koenigs et al. 2007). 
Dorsolateral prefrontal cortex (DLPFC) involves mainly BA9 and 46 but also BA 6, 8 
and 10 depending on reference. DLPFC is greatly involved in executive functions and 
working memory with dopamine modulation (Smith, Jonides 1999, Funahashi 2006, 
Arnsten 2009, Goldstein, Volkow 2011). 
Frontopolar cortex (BA10) is suggested to function in cognitive branching enabling to 
hold primary goals in mind during the multitasking (Koechlin, Hyafil 2007). Orbitofrontal 
cortex (BA11) is a part of decision making, expected reward situations and adaptive 
learning (Schoenbaum et al. 2011).  
Pars opercularis and pars triangularis in frontal lobe involve the Broca’s area on the left. 
Wernicke’s area is located in temporal lobe. Broca’s area is crucial for producing speech 
and also involved in language comprehension, language processing and facial neuron 
control. Whereas, Wernicke’s area is rather responsible for comprehension of language, 
semantic processing, language recognition and interpretation (Damasio, Geschwind 1984). 
Anterior cingulate cortex (ACC) including BA 24, 32, and 33, is suggested to be 
ubiquitously active brain area involved in motor control, emotional self-control and in 
cognition by means of decision making (focused problem solving, error recognition and 
adaptive response to changing conditions) and it has been found to be involved in many 
psychiatric disorders (Allman et al. 2001, Paus 2001, Wallis, Kennerley 2011). 
The posterior cingulate cortex (BA23, 31) is a part of the default mode network, a set of 
brain regions that are highly active during rest. It has been suggested that it has a role in 
creativity and creation of spontaneous thoughts, being relevant to major mental or 
cognitive disorders (Buckner, Andrews-Hanna & Schacter 2008). Posterior cingulate cortex 
is suggested also to be involved in eye movements, spatial attention and navigation 
(Kravitz et al. 2011). 
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Retrosplenial cortex (BA 26, 29, 30) projecting to the anterior thalamic nuclei and 
hippocampus is involved in episodic and spatial memory, navigation, imagination and 
planning for the future (Vann, Aggleton & Maguire 2009). Furthermore, neurocognitive 
studies and case reports indicate that patients with damaged retrosplenial cortex have 
spatial orientation deficit and difficulty acquiring new visual or verbal information 
(Maguire 2001).  
Perirhinal cortex contributes to the higher-order visual perception and complex 
conjunctions of objects and storaging of this visual data in memory (Murray, Bussey & 
Saksida 2007). Fusiform gyrus is especially involved in the perception of faces (Kanwisher, 
McDermott & Chun 1997) but it also has highly selective neural populations for 
recognition of non-facial objects (Grill-Spector, Sayres & Ress 2006).  
Finally, mice studies have shown that the piriform cortex is a highly seizure-prone 
region (Piredda, Gale 1985). 
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2.3.4 Thalamus and basal ganglia 
Thalamus is an oval-shaped relay centre of diencephalon between subcortical areas and 
the cerebral cortex. Thalamus consists of 50-60 nuclei that project via afferents and 
efferents to the well-defined cortical areas. With the exception of olfactory system, every 
sensory system includes a thalamic nucleus that contralaterally receives specific sensory 
signals and sends back information to different thalamic nuclei via basal ganglia. (Herrero, 
Barcia & Navarro 2002) These signalling pathways are known as cortical-striatal-pallidal-
thalamic-cortical circuits that include motor, oculomotor, dorsolateral prefrontal, lateral 
orbitofrontal and anter cingulate circuits.  (Green, Ostrander 2009) 
Pathology in thalamus leads to disturbances in motor and sensory systems, as well as 
central pain or anaesthesis in the opposite side of the body. (Herrero, Barcia & Navarro 
2002). More specifically, lesions confined to the specific nuclei have been associated with 
asterixis (Lee, Marsden 1994), cheiro-oral syndrome (Shintani, Tsuruoka & Shiigai 2000) or 
choreiform and dystonic movements associated with myorhythmia (Lera et al. 2000). 
Lesions of both thalamus and basal ganglia are related to dystonia (Lee et al. 1994). 
Importance of thalamus in fine motor control is well demonstrated by deep brain 
stimulation (DBS) of ventral intermediate nucleus of thalamus used as treatment in 
essential tremor that is the most common movement disorder in the world (Zesiewicz et 
al. 2013). Eventually, thalamus is best known for its multiple functions both in sensory and 
motor aspects, but thalamus is also involved in cognitive functions for example the 
regulation of awareness, attention, memory and language (Smythies 1997, Buchel et al. 
1998, Johnson, Ojemann 2000).  
Basal ganglia are a group of nuclei located at the base of forebrain. Basal ganglia are 
named in several ways that leads to difficulty to memorize parts of it (Figure 2). Putamen 
together with caudate nucleus and nucleus accumbens forms striatum which is the major 
part of basal ganglia. Basal ganglia are a part of extrapyramidal motor system regulating 
automatic and voluntary movements, movement initiation and spatial working memory, 
and processes of behaviour, learning and planning (Herrero, Barcia & Navarro 2002, 
Graybiel 2005, Yin, Knowlton 2006). Putaminal pathology is related to motor stereotypies 
like fine resting tremor, hyperkinetic movement disorders like Huntington disease and 
hypokinesia disorders including Parkinson’s disease (Herrero, Barcia & Navarro 2002, 
Turner, Desmurget 2010). All these disorders also possess cognitive impairment and basal 
ganglia are also related to behavioural disorders like schizophrenia and obsessive 
compulsive disoders (Herrero, Barcia & Navarro 2002, Green, Ostrander 2009). 
Interestingly, microstructural and volumetric abnormalities of the putamen have been 
observed also in juvenile myoclonic epilepsy (Keller et al. 2011) which share some similar 
clinical characters with EPM1.  
To summarise, the thalamus and striatum are important not only in motor control, but 
also in higher-order cognitive and behavioural processes. 
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Figure 2. Thalamus and basal ganglia are located symmetrically within the middle of the brain. 
 
 
2.4 MODERN ANALYSIS METHODS FOR MRI OF THE BRAIN  
2.4.1 Cortical Thickness Analysis 
Subtle pathological changes of the neurological diseases are characteristically too complex 
or diffuse to be detected by human visual system in MR images because of limitations on 
the resolution of MRI. (Ashburner et al. 2003) In recent years, new software has brought 
improved tools to investigate cerebral cortex in detail. Cortical thickness analysis (CTH) 
enables an automated and objective method to detect subtle changes in the brain in vivo 
using MR imaging (Fischl, Dale 2000). 
 There are several methods developed for the CTH analysis. A widely used CTH 
analysis is conducted by using the pipelining method developed at the McConnell Brain 
Imaging Centre, Montreal Neurologic institute, McGill University Montreal, Canada 
(http://www2.bic.mni.mcgill.ca).  
In CTH, when the basic protocol is gone over step by step (Figure 3), the individual MR 
image volumes are; first, spatially normalized to the same stereotactic template (Mazziotta 
et al. 2001), secondly, intensity inhomogeneities are corrected (Sled, Zijdenbos & Evans 
1998) and lastly, extracerebral voxels are removed with a stereotactic brain mask (Smith 
2002).  
Following with, the magnitude of the partial volume effect is estimated for each voxel 
(Tohka, Zijdenbos & Evans 2004) and brain tissue is divided into grey matter (GM), white 
matter (WM), and CSF (Zijdenbos 1998). The brains are automatically divided into two 
separate hemispheres and the inner and outer surfaces of the cortex are extracted by using 
automated segmentation (Kim et al. 2005) followed by identification of white matter 
surface (WMS) i.e. the surface between WM and GM and grey matter surface (GMS) i.e. 
the surface between GM and CSF. The thickness of the cortex is defined with a t-link 
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metric at each linked node as the distance between WMS and GMS and as a result a CTH 
map can be acquired (Lerch, Evans 2005). For further analyses, the thickness calculations 
are performed on each subject’s native space and are then transformed back to the 
standard space for the group analysis. Finally, the data are smoothed to improve the 
signal-to-noise ratio and statistical power (Chung, Taylor 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. In short, the steps of CTH. A) Individual MR images are registered to the standard 
space and corrected for artefacts before the final brain mask is created. B) Brain tissue is 
divided into GM, WM and CSF. C) Inner (WM/GM) and outer (GM/CSF) surfaces of the cortex 
are extracted. D) Finally, the results are visualized in colors. 
 
2.4.2 Cortical thickness in diseases 
CTH analysis has been applied both to investigate neuroanatomy and individual variation 
in cerebral cortex and to explore how various diseases are related to the cortical 
alterations. One of the first applications of CTH analysis was in Alzheimer’s disease (Lerch 
et al. 2005) where widespread cortical thinning was demonstrated in patients with AD 
compared to the healthy controls. Afterwards, several research projects on the effects of 
aging, mild cognitive impairment and AD, has been published (Julkunen et al. 2009, 
Vuorinen et al. 2013). CTH has been applied also in other common neurodegenerative 
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diseases like in frontotemporal dementia, multiple sclerosis and Parkinson disease 
(Calabrese et al. 2010, Lyoo, Ryu & Lee 2011, Hartikainen et al. 2012). 
Several psychiatric related disorders have been linked in the cerebral cortex. Regional 
cortical thinning has been found in different parts of frontotemporal areas in 
schizophrenia, obsessive-compulsive disorder, psychopathy and violent antisocial 
personality disorder (Kuperberg et al. 2003, Kuhn et al. 2012, Ly et al. 2012, Narayan et al. 
2007). Morphometric alterations of cerebral cortex have been studied even in white collar 
criminals (Raine et al. 2012). 
In epilepsy, CTH has been applied to detect possible cortical differences in different 
neuropsychological phenotypes. In a temporal lobe epilepsy (TLE) study patients were 
divided in three cognitive clusters and were compared with each other and with healthy 
controls (Dabbs et al. 2009). The patients with the most impaired cognition exhibited the 
most significant cortical thinning that was evident throughout the cerebral cortex 
compared to the healthy controls. The most impaired cluster also had thinner cortex than 
the minimally impaired patient cluster in the bulk of parietal lobe and cuneus, and 
unilatelar parts of temporal and frontal lobes.  
Correlation between cognitive scores (IQ, executive function and verbal episodic 
memory) and cortical thickness were studied in patients with only TLE and TLE with 
interictal psychosis and healthy controls. Cortical thickness differed between groups but 
no correlations were found between cortical thickness and cognitive scores in the groups 
(Gutierrez-Galve et al. 2012). 
Tosun et al. compared patients with childhood absence epilepsy with healthy children 
and found abnormal age-related thinning in the right posterior central gyrus and posterior 
part of the superior temporal gyrus, lingual gyrus, and paracentral gyrus and thickening 
in the parts of left hemisphere (Tosun et al. 2011b). Patients with epilepsy had same mean 
VIQ and PIQ scores in the average range and the study findings suggested that patients 
with epilepsy use different brain regions to perform these cognitive functions compared to 
healthy controls.  
Tosun et al. studied complex partial seizures (CPS) and found that patients with below 
average IQ’s showed significantly greater cortical thinning with age than the control 
group, widespread in both the left and right hemispheres, however they also had thicker 
cortex in some parts of the brain (left fronto-temporal cortex, left lateral occipital cortex, 
right fusiform cortex) with older age than the normal group (Tosun et al. 2011a). They 
concluded that there is disruption of cortical thickness expression associated with 
intelligence in children with CPS.  
Recently it has been found that valproate is related to overall decrease in brain volume, 
white matter volume and parietal lobe thinning (Pardoe, Berg & Jackson 2013). The study 
was performed by comparing valproate users, non-users and healthy controls in two 
different types of epilepsy, intractable focal epilepsy and child-hood onset epilepsy. 
Finally, it has been demonstrated that carriers of ε4 allele of apolipoprotein E gene, a 
risk allele for Alzheimer disease, have significant cortical thinning of entorhinal cortex 
compared to non-carriers, which may be identifiable already in childhood (Shaw et al. 
2007). This finding demonstrates that there may be a lot of intrinsic and extrinsic factors 
which affect the thinning or thickening of the cerebral cortex and topography of the cortex 
varies individually (Krubitzer, Seelke 2012). 
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2.4.3 Texture Analysis 
2.4.3.1 Introduction to the texture analysis 
There are several definitions for texture in literature. Texture is an arrangement and 
interrelationship of parts in an object. It can be described for example as irregular, fine, 
coarse, smooth or rippled (Haralick 1973). Texture is present everywhere; it can be seen in 
the images, touched from the textiles and heard in music. In images, including medical 
imaging, texture is a surface property that has a peculiar arrangement, but the ability of 
human vision to detect these pictorial details is limited (Julesz 1973). Differences in 
textures help to discriminate between various objects and help to develop applications to 
detect subtle differences between them (Figure 4). 
Texture analysis (TA) is a method for evaluating the textural features of an object. 
Initially, it was developed for the evaluation of aerial photographs (Kaizer 1955, Hall et al. 
1971), and shortly after it was applied to the medical imaging (Hall et al. 1971, Chien 
1974). The basic idea of texture analysis is to provide advanced, non-visible information 
about areas of interest in an object or image. Thus, in radiology TA enables detection of 
differences between tissues and classifies them automatically. It can be applied in any 
digital image and numbers of studies have reported applications in x-ray, computed 
tomography, ultrasound and magnetic resonance imagining. (Castellano et al. 2004, Holli 
2011, Harrison 2011) Eventually, TA can be a useful tool for computer-aided diagnosis 
(CAD), a set of electromedical procedures to help physicians and radiologists to interpret 
medical images (Tourassi 1999). Besides the medical imaging and biomedical surface 
inspection, TA is applied in industrial use in a shape of robots that use “the machine 
vision”, one of the hot topics in research and computer image analysis (Szczypinski et al. 
2009). For example, in food industry, robotic machine vision can assist to detect differences 
between various substances and can find contaminated or defective food, and in forest 
industry texture analysis can help to identify wood species from each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Examples of different kind of textures. 
28 
 
 
2.4.3.2 Texture analysis methods and texture features 
In medical imaging texture analysis is a method for assessment of the position and 
intensity of pixels (2D picture elements) or voxels (3D volume elements) and their grey-
level intensity in a digital image. Thus, every pixel or voxel has a peculiar coordinate and 
grey-level value. Texture features are mathematical parameters based on the distribution 
of pixels or voxels, which qualify the texture type and structure of the object. Texture 
methods process the information of pixel/voxel distribution resulting in texture 
parameters. (Castellano et al. 2004) 
There are four major categories of texture methods given in the literature: 
 Statistical methods were the original way of calculating the texture features 
introduced in the 1970’s (Haralick 1973). First-order statistics calculate image 
properties from the features of individual pixel or voxel whereas second-order 
statistics describe the properties of pixel or voxel pairs. Higher order statistics 
represent image properties calculated from three or more pixels. Statistical methods 
include histogram-, absolute gradient-, autocorrelation function-, run-length 
matrix- and co-occurrence matrix-based texture parameters. (Castellano et al. 2004, 
Tuceryan, Jain 1998) Co-occurrence matrix-based features seem to be usable for 
discriminating image properties and they are the most commonly used in medical 
image analysis (Haralick 1979). 
 Geometrical or structural methods define texture by using the local mathematical 
expressions i.e primitive elements from which another expression is derived. This 
means that a square object is represented in terms of the straight line shapes. 
Basically, these methods are better for the synthesis of an image than for its analysis 
and are not used as widely than the other texture methods. (Castellano et al. 2004, 
Tuceryan, Jain 1998) 
 Model-based methods use sophisticated mathematical models to describe an image 
by generating an empirical pixel-weighted model of each pixel. In other words, 
these methods both describe and synthesize the texture of an image. (Tuceryan, Jain 
1998) Model-based methods comprise autoregressive (AR) models (Haralick 1979), 
Markov random fields and fractal features (Tuceryan, Jain 1998). A mutual 
character of these models is that they make estimates of pixel or voxel intensities 
where the texture parameters are derived. The calculations of these parameters are 
very complex that causes computational limitations for these methods.  
 Signal-processing or transform methods filter information from an image by 
executing the frequency analysis of its texture. Frequency analysis is based on that 
there is a characteristic distribution of pixels or voxels in an object and these pixels/ 
or voxels and their combinations occur in an image with varying frequencies. 
Fourier transform is one of the best known signal-processing applications. Also, 
Gabor and Wavelet transform-based methods are widely used in image texture 
analysis. (Castellano et al. 2004, Tuceryan, Jain 1998) 
 
2.4.3.3 Software packages for texture analysis 
There are various texture analysis softwares, also freely available on Internet. One of these 
is a product of European cooperation, MaZda MRI texture analysis software package. 
MaZda was initially developed for MR image analysis by Materka and co-workers 
(Institute of Electronics in the Technical University of Lodz, Poland) being a part of the 
Quantitation of Magnetic Resonance Image Texture project (COST B11 project, 1998–2002) 
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conducted by European Cooperation in Science and Technology (COST). (Szczypinski et 
al. 2009) 
Before the texture analysis is performed, the suitable images must be picked and 
converted into the right format if necessary. The 2D version of Mazda reads image file 
formats that the common manufacturers use including .bmp, .ima, .img, .xim, .dicom, 
.dcm and unformatted (.raw).  The 3D version of MaZda reads the dicom (.dcm; .dicom), 
Windows bitmap (.bmp) and floating point 3D data (.bmf), and unformatted (.raw).  
First the appointed image (2D) or image package (3D) is opened in the MaZda program, 
then the regions of interest (ROI) in 2D or volumes of interest (VOI) in 3D are placed in an 
image by manually or semi-automatically drawing them on the image (Figure 5). Before 
the texture parameter calculations, image grey level intensity normalization computation 
is performed for each region or volume of interest. There are method limiting image 
intensities in the range [μ-3σ, μ+3σ], where μ is the mean grey level value and σ the 
standard deviation. This method has been shown to intensify differences between two 
classes when comparing image intensity normalization methods in texture classification 
(Collewet, Strzelecki & Mariette 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A view of MaZda during the ROI drawing. The blue areas represent an active ROIs 
ready for the further analysis and the red ball is an inactive ROI. 
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After these steps, the texture parameter calculations are conducted.  
MaZda version 4.60 calculates almost 300 texture parameters based on histogram, 
gradient, run-length matrix, co-occurrence matrix, autoregressive model and wavelet-
derived parameter feature sets (Szczypinski et al. 2009). Most of the parameters are pure 
mathematical definitions but some of the texture parameters have also a descriptive 
meaning (see also Table 13 on page 71). 
 Histogram 
o Histogram-based statistics assess the global distribution of pixels/voxels 
with specific grey level tones (Castellano et al. 2004). Several statistical 
properties can be calculated from the histogram. The mean is the average 
intensity level of the image, variance assesses the roughness of an image, 
skewness describes the histogram symmetry and kurtosis describes the 
flatness of the histogram. (Materka, Strzelecki 1998) 
 Gradient 
o The spatial variation of grey-level values across the image is described by 
the gradient. Thus, high values mean that the grey level varies suddenly 
from black to white whereas when variation of grey levels is smooth, the 
gradient value is low (Castellano et al. 2004). Gradient based parameters 
are mean, variance, skewness, kurtosis and percentage of pixels with 
non-zero gradient.  
 Run-length matrix 
o A gray level run is a set of consecutive picture points i.e. when two or 
more pixels/voxels have the same value in a present direction (Galloway 
1975). RLM-based parameters assess the number of runs and they 
describe the coarseness or smoothness of an image.  
 Long and short run emphases assess the proportions of runs. The 
value of short run emphasis is larger in more coarse images and 
the value of long run emphasis is larger in smoother images.  
 Gray level non-uniformity calculates how uniformly the runs are 
distributed among the gray levels; smaller values indicate that the 
distribution of runs is more uniform.  
 Run length non-uniformity gets low values if the runs are evenly 
distributed over all runs lengths. 
 Run percentage or fraction of image runs has low value in images 
with the most linear structure. 
 Co-occurrence matrix 
o Entropy indicates the complexity and randomness within the image. It is 
inversely correlated with angular second moment. Images with more 
gray levels have higher average entropy and lower average angular 
second moment (Haralick 1973). When the image is not texturally 
uniform then the value of entropy is higher, whereas, the higher value of 
angular second moment feature indicates that the intensity varies less in 
the image is more homogenous. 
 Autoregressive model parameters take in consideration also the neighbouring 
pixels/voxels, in consequence each pixel grey level value is a weighted sum of 
values from neighbour pixels (Castellano et al. 2004). In MaZda, Theta (model 
parameter vector, 4 parameters) and Sigma (standard deviation of the driving 
noise) can be calculated. 
 Wavelet transform is a section of signal analysis or signal processing that deals 
with a complex time varying and spatially varying physical properties of an 
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object, signals. Signals can be from sound, electromagnetic radiation or like in 
this case, image.  Wavelet-derived parameters analyse the frequency content of a 
variously scaled picture signal. (Castellano et al. 2004) They are complex 
mathematical patterns and MaZda generates parameters based on Haar wavelet 
groups (energy of the wavelet coefficients in subbands) (Szczypinski et al. 2009).  
 
2.4.3.4 Texture analysis applications in medical imaging 
MR images contain a huge amount of pictorial and textural information, and in a PubMed 
search on texture analysis, the majority of literature has been applied in MRI, but also x-
ray and CT applications can be found. Texture analysis has been experimentally applied in 
several medical conditions and syndromes, for example: to detect osteoporotic changes 
(Link et al. 1999); to differentiate benign soft tissue tumours from malignant tumours 
(Juntu et al. 2010); to classify brain tumours (Herlidou-Meme et al. 2003) to detect textural 
changes in mild brain injury (Holli et al. 2010b); to classify liver lesions (Mayerhoefer et al. 
2010); to assess the degree of liver fibrosis (Kato et al. 2007);  to provide a prognostic factor 
in colon CT in patients with colorectal cancer (Ng et al. 2013); to characterize different 
breast cancer types (Holli et al. 2010a); and to correlate with the histopathologic finding of 
non-small cell lung cancer (Ganeshan et al. 2013). Publications are also found in the most 
common brain diseases, which include Alzheimers disease (Zhang et al. 2012), Parkinson 
disease (Sikiö et al. 2011), schizophrenia (Ganeshan et al. 2010) and multiple sclerosis 
(Zhang 2012). The following chapters focus mainly on neuroradiological MRI applications 
of texture analysis. 
 
Texture analysis in epilepsy 
In epilepsy research, TA has been applied in temporal lobe epilepsy (TLE), focal cortical 
dysplasia and juvenile myoclonic epilepsy (JME) (Yu et al. 2001, Bonilha et al. 2003, Jafari-
Khouzani et al. 2010, Alegro et al. 2012, Antel et al. 2003, Bernasconi et al. 2001, de Oliveira 
et al. 2013).  
In patients with unilateral temporal lobe epilepsy (TLE) with ipsilateral hippocampal 
sclerosis (n= 23) 2D TA was applied to characterize abnormalities on MR images of 
hippocampi (Yu et al. 2001). The study showed abnormalities in apparently normal 
contralateral hippocampi that remained normal in visual assessment. Furthermore in 
mesial TLE (n=19) textural differences were found between both proven hippocampal 
sclerosis and contralateral side, and between normal hippocampi in almost all texture 
parameters (Bonilha et al. 2003). The most significantly differing parameters were short 
run emphasis, fraction of image in runs, difference of entropy and sum entropy. No 
changes were found between proven hippocampal sclerosis and contralateral hippocampi. 
Additionally, study on mesial TLE (n=36) was able to show that the analysis of mean and 
standard deviation of 1.5 T fluid attenuation inversion recovery (FLAIR) images was able 
to detect the lateralization of the epileptic focus with an accuracy of 98 %. Whereas, for 
wavelet texture features, the accuracy was 94 % (Jafari-Khouzani et al. 2010). The most 
recent article continued the study of accuracy in mesial TLE (n=12) combined with 
histological data from recently removed hippocampi. MRI texture parameters were able to 
classify the hippocampal tissues according to the clinical history (Alegro et al. 2012). 
In focal cortical dysplasia studies from Antel, Bernasconi and co-workers first-order 
statistics- and co-occurrence matrix-based TA parameters were applied in detection of 
focal lesions in cerebral cortex (Antel et al. 2003, Bernasconi et al. 2001). Automated co-
occurrence matrix-based TA classifier was able to identify 17 lesions from 20 manually 
labeled lesions (Antel et al. 2003).  
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In a recent study, TA was applied in juvenile myoclonic epilepsy (n=24) that has the 
same characteristic symptoms as EPM1: age onset from 12 to 18 years, myoclonus and 
tonic–clonic seizures. The parameters based on co-occurrence matrix were used in 2D 
image slices in 3 segments in right and left thalamus, no other structures or other texture 
features were evaluated in this study (de Oliveira et al. 2013). The study reported a 
difference in right thalami and the differing features included contrast, difference 
variance, difference entropy, sum of squares, and inverse difference moment from 
distances 3–5. No changes were found in left thalami. 
 
Texture analysis of inherited neurodegenerative disease 
Machado-Joseph disease or spinocellar ataxia type 3 is a rare autosomal dominantly 
inherited neurodegenerative disorder which causes progressive cerebellar ataxia and 
motor dysfunction. TA based on co-occurrence matrix was applied in Machado-Joseph 
disease patients (n=18) where ROIs were placed in image slices of corpus callosum, 
thalamus, putamen and caudate nuclei (de Oliveira et al. 2012). The most significant 
textural changes between controls and patients were found in caudate nuclei and left 
thalamus in line with previous histopathological and imaging studies. The authors 
pointed out that single feature textural differences were crucial for detection of 
differences. 
 
Three-dimensional texture analysis applications 
Theoretically, three-dimensional (3D) texture analysis provides more comprehensive data 
analysis of biological tissue texture properties and enables calculation of texture 
parameters in several directions.  However, the literature on 3D TA applications in brain 
research is still sparse (Zhang et al. 2012, Kovalev, Kruggel & von Cramon 2003, 
Mahmoud-Ghoneim et al. 2003, Chen et al. 2007, Kocinski et al. 2012, Georgiadis et al. 
2009). 
Thus far, literature on texture analysis in radiological research is limited. The majority 
of the published studies are based on small study groups. Nonetheless, recent studies in 
the field of radiology have shown promise in the feasibility of TA also in medical imaging. 
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3 Aims of the study 
 
The general aim of this thesis was to identify and characterize radiological findings of 
patients with EPM1 and to find possible correlations between radiological findings and 
phenotype of EMP1.  More specifically, the aims were: 
 
 
I To study the possible skeletal abnormalities of patients with EPM1 by 
measuring the regional calvarial thicknesses from three-dimensional MR 
images and by evaluating the skeletal structures of the patients from clinical 
X-rays and CTs. 
 
 
II To evaluate regional cortical thinning and its possible relation to 
neurocognitive function in EPM1 by cortical thickness analysis (CTH). 
 
 
III To investigate possible imperceptible structural differences in thalamus and 
other deep gray matter tissue in patients with EPM1 in comparison with 
healthy controls by using three-dimensional MRI-based texture analysis. 
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4 Thickened skull, scoliosis and other skeletal findings in 
Unverricht-Lundborg disease link cystatin B function to 
bone metabolism 
 
ABSTRACT 
 
Purpose 
Unverricht-Lundborg disease (EPM1) is a rare type of inherited progressive myoclonic 
epilepsy resulting from mutations in the cystatin B gene, CSTB, which encodes a cysteine 
cathepsin inhibitor. Cystatin B, cathepsin K, and altered osteoclast bone resorption activity 
are interconnected in vitro. This study evaluated the skeletal characteristics of patients 
with EPM1. 
 
Methods 
Sixty-six genetically verified EPM1 patients and 50 healthy controls underwent head MRI. 
Skull dimensions and regional calvarial thickness was measured perpendicular to each 
calvarial bone from T1-weighted 3-dimensional images using multiple planar 
reconstruction tools. All clinical X-ray files of EPM1 patients were collected and reviewed 
by an experienced radiologist. A total of 337 X-ray studies were analyzed, and non-
traumatic structural anomalies, dysplasias and deformities were registered. 
 
Results 
EPM1 patients exhibited significant thickening in all measured cranial bones compared to 
healthy controls. The mean skull thickness was 10.0 ± 2.0 mm in EPM1 patients and 7.6 ± 
1.2 mm in healthy controls (p<0.001). The difference was evident in all age groups and was 
not explained by former phenytoin use. Observed abnormalities in other skeletal 
structures in EPM1 patients included thoracic scoliosis (35% of EPM1 patients) and lumbar 
spine scoliosis (35%), large paranasal sinuses (27%), accessory ossicles of the foot, and 
arachnodactyly (18%). 
 
Conclusions 
Skull thickening and an increased prevalence of abnormal findings in skeletal radiographs 
of patients with EPM1 suggest that this condition is connected to defective cystatin B 
function. These findings further emphasize the role of cystatin B in bone metabolism in 
humans. 
  
4.1 INTRODUCTION 
Progressive myoclonic epilepsies (PMEs) comprise a multiform group of rare, usually 
inherited neurodegenerative syndromes marked by myoclonus, epilepsy and progressive 
neurological deterioration (Shields 2004). Progressive myoclonic epilepsy type 1 or 
Unverricht-Lundborg disease (EPM1, ULD, OMIM 254800) is the most common single 
cause of PME. EPM1 has the highest prevalence in Finland (incidence 1:20 000 births per 
year, about 200 diagnosed cases), but it is also prevalent elsewhere in the Baltic Sea region 
and in the Western Mediterranean area. Sporadic cases of EPM1 have been reported 
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worldwide (Kälviäinen et al. 2008). 
Clinically, EPM1 is characterized by stimulus-sensitive myoclonus and tonic-clonic 
epileptic seizures. The age of onset is age 6–16 years, and the progressive symptoms 
typically include ataxia, balance and motor dysfunctions, dysarthia and dysphagia. About 
one-third of EPM1 patients become severely incapacitated, but the clinical symptoms can 
be so mild that there is a delay in the diagnosis. Accordingly, typical clinical 
manifestations and neurophysiological findings in a child that previously appeared to be 
healthy eventually lead to the clinical diagnosis of EPM1, which can then be confirmed by 
mutation analysis (Kälviäinen et al. 2008). 
Clinical studies of EPM1 have concentrated on the neurological and neurophysiological 
findings. There are few imaging studies, and most of them have focused on the brain. MRI 
studies reveal mild to moderate cerebral and/or cerebellar atrophy, loss of neuronal 
volume in the brainstem and changes in the basal ganglia (Koskenkorva et al. 2009, Chew 
et al. 2008, Mascalchi et al. 2002, Korja et al. 2007b, Santoshkumar, Turnbull & Minassian 
2008, Korja et al. 2010). 
Mutations in the CSTB gene, which encodes cystatin B, are responsible for the primary 
defect in EPM1 (Pennacchio et al. 1996). The result of these mutations is substantially 
reduced CSTB gene and protein expression in the majority of cases (Joensuu, Lehesjoki & 
Kopra 2008). Some patients with a phenotype similar to EPM1 have mutations in the 
PRICKLE1, SCARB2 or GOSR2 genes (Bassuk et al. 2008, Corbett et al. 2011, Dibbens et al. 
2009). Although the CSTB protein has been reported to act as an inhibitor of cysteine 
cathepsins (Green et al. 1984, Leist, Jaattela 2001), its physiological function remains 
largely unknown. Studies in mice implicate oxidative stress and early microglial activation 
as factors that contribute to EPM1 pathogenesis  (Tegelberg et al. 2012, Lehtinen et al. 
2009). 
Interestingly, CSTB has also been suggested to play a role in bone resorption (Laitala-
Leinonen et al. 2006). Thus far, few studies have documented bone findings in EPM1 
patients. Koskiniemi et al. first described thickening of the skull and thoracic scoliosis in 
EPM1 patients in 1974 (Koskiniemi et al. 1974). Subsequently, thickening of the calvarium 
in four EPM1 patients was interpreted as hyperostosis frontalis interna (HFI) (Korja et al. 
2007a). HFI is considered a benign symmetric nodular protrusion of the inner table in the 
frontal bone with an unknown etiology (She, Szakacs 2004). We hypothesized that in 
addition to the previously reported thickening of the frontal bone, EPM1 may be 
associated with more extensive calvarial changes and possibly with other skeletal changes. 
To investigate this hypothesis, we examined bone structures in a series of 66 patients with 
genetically verified EPM1. Three-dimensional MRI was used to evaluate possible 
hyperostosis or other abnormalities in the cranial bones in detail, and the perpendicular 
skull thickness was measured in the frontal, parietal, temporal and occipital areas. Fifty 
healthy subjects served as controls. In addition, we retrospectively evaluated all clinical 
bone X-rays of these 66 EPM1 patients to identify any structural abnormalities.  
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4.2 PATIENTS AND METHODS 
4.2.1 Study design 
For this study, 66 EPM1 patients were evaluated at Kuopio University Hospital between 
2008 and 2010. The patient group included 35 men and 31 women, with a mean age of 33 ± 
12 years (range, 12–65 years), who were participating in an ongoing clinical and molecular 
genetics study at the Kuopio Epilepsy Center, Kuopio University Hospital. This study was 
jointly administered by the Folkhälsan Institute of Genetics and Neuroscience Center at 
the University of Helsinki. The patients had either participated in an earlier molecular 
genetics study or were referred to the Kuopio Epilepsy Center during the study. Of the 
EPM1 patients, 61 were homozygous for the dodecamer expansion mutation, while 5 were 
compound heterozygous for the expansion and the R68X mutations. The control group 
included 50 healthy subjects, 26 men and 24 women, with a mean age of 41 ± 15 years 
(range, 18–75 years). The ethics committee at the Kuopio University Hospital approved the 
study, and written informed consent was obtained from all participants. 
4.2.2 Clinical assessment of patients with EPM1 
The medical histories of EPM1 patients were determined from medical records and by 
interviewing the patients and their relatives. The mean onset age was 10 ± 3 years (range, 
5–25 years), and the mean duration of the disorder was 23 ± 11 years (range, 4–44 years). 
All of the patients were treated with antiepileptic drugs (AEDs). Table 5 lists the EPM1 
patients’ medications. 
 
Table 5. Antiepileptic medications (AED) taken by the 66 EPM1 patients. 
Medication (n) Number of AEDs (n) Former phenytoin use (n) 
Valproate 65 Monotherapy 1 Several years 2 
Clonazepam 48 2 AEDs 19 Temporarily 17 
Levetiracetam 45 3 AEDs 25 Never 43 
Topimarate 14 4 AEDs 19 Unknown 4 
Piracetam 12 5 AEDs 2   
Lamotrigine 10     
Clobazam 3     
Phenobarbital 3     
4.2.3 MRI and data analysis 
The subjects underwent MR imaging (1.5 T, Siemens Avanto, Erlangen, Germany), and the 
structures of their skulls were evaluated from T1-weighted 3-dimensional images 
(MPRAGE, TR 1980 ms, TE 3.09 ms, flip angle 15°, matrix 256 x 256, 176 sagittal slices, slice 
thickness 1.0 mm, in-slice resolution of 1.0 mm x 1.0 mm). 
Skull dimensions and local skull thickness were measured in the middle of each 
calvarial bone on a picture and archiving communication system workstation (Sectra 
workstation IDS5, version 11.1.P3; SectraImtec AB; Linkoping, Sweden) using the multiple 
planar reconstruction tool to achieve orientations perpendicular to the bone. A single 
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observer (SS) who was blinded to the subject’s status (patient or control) measured the 
calvarial dimensions in all patients and controls according to a fixed measuring paradigm 
(Figure 6). To assess the repeatability of the measurements, a second observer (RL) 
measured the skull thickness in 75 individuals. The following measurements were 
performed: 1) internal and external dimensions of the skull in the coronal, sagittal and 
caudocranial directions; and the thickness of the 2) frontal bones (bilateral), 3) parietal 
bones (bilateral), 4) occipital bones (bilateral) and 5) temporal bones (bilateral) at the 
coronal level of the external auditory meatuses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The mean thickness of each cranial bone was evaluated by calculating the average of 
the bilateral measurements of A) frontal bones from the coronal plane between the sagittal 
suture and the coronal suture; B) parietal bones from the coronal plane at the thickest point; 
C) occipital bones from the axial plane circa 20 mm above the AC-PC line between the sagittal 
suture and lambdoidal suture; and D) temporal bones at the coronal level of the external 
auditory meatuses. 
 
The total intracranial volume (ICV) of the brain was evaluated using optimized voxel-
based morphometry (VBM) with the VBM2 toolbox (http://dbm.neuro.unijena/vbm/) in 
SMP2 (Wellcome Department of Imaging Neuroscience, London, UK; 
www.fil.ion.ac.uk/spm) running under Matlab 6.5 (The MathWorks, Inc., Natick, MA) 
(Koskenkorva et al. 2009). Briefly, customized template and prior probability maps were 
created from T1-weighted 3-dimensional images, and then the primary VBM steps were 
performed, including normalization of the original magnetic resonance images and 
segmentation of normalized images. The absolute volumes of gray matter (GM), white 
matter (WM) and cerebrospinal fluid (CSF) were calculated from the segments. Finally, the 
GM, WM and CSF compartments were added to obtain the total ICV. The absolute 
volumes of these compartments and the ICV of 34 EPM1 patients were published 
previously (Koskenkorva et al. 2009). 
4.2.4 X-ray and computed tomography (CT) analysis 
The X-ray files of all 66 EPM1 patients were obtained from the patients’ medical 
institutions and reviewed by an experienced radiologist (HM) and a resident (SS). X-ray 
films suitable for analyzing bones, spine or joints were identified in 61 patients. A total of 
337 X-ray images were analyzed, and structural anomalies, dysplasias and deformities 
were registered. Osteoarthritis and other degenerative joint findings and fractures were 
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excluded from the evaluation. CT scans were evaluated when available to determine bone 
features in greater detail. 
4.2.5 Statistical analysis 
All statistical analyses were performed with the statistical software SPSS 17.0 for Windows 
(IBM SPSS Inc., Chigaco, IL). Differences were considered to be statistically significant 
when the P value was <0.05. The independent sample t-test was used for comparisons 
between groups, and correlation coefficients were calculated by Pearson’s correlation test. 
The mean thickness of a cranial bone was determined by calculating the average of the 
bilateral measurements. Analysis of covariance (ANCOVA) was employed to determine 
the influence of different factors (age, onset age, duration of the disease, height, ICV) on 
the skull thickness of EPM1 patients, with gender and former phenytoin use as 
independent variables. Clinically relevant and potential predictors that showed 
statistically significant associations with the mean skull thickness in univariate analyses 
were included in ANCOVA. The intraclass correlation coefficient (ICC) was used to assess 
reproducibility and agreement of measurements between two readers (SS and RL) in 75 
random subjects. (Landis, Koch 1977). The intraobserver reproducibility between skull 
thickness measurements was excellent. The intraclass correlation coefficient was 0.929. The 
mean skull thicknesses for 75 random subjects were 9.7 ± 2.1 mm (Observer A) and 9.4 ± 
2.2 mm (Observer B), and no significant statistical difference in the mean values of the 
Observer A and B was found. 
 
4.3 RESULTS 
EPM1 patients exhibited significant calvarial thickening in all measured cranial bones 
compared to healthy controls (Table 6). The mean skull thickness was 10.0 ± 2.0 mm in 
EPM1 patients and 7.6 ± 1.2 mm in healthy controls (p<0.001). The most remarkable 
alterations were in the frontal bone (11.4 ± 3.1 mm vs. 6.6 ± 1.7 mm, p<0.001), parietal bone 
(9.4 ± 2.3 mm vs. 7.1 ± 1.6 mm, p<0.001) and temporal bone (2.4 ± 0.8 mm vs. 1.6 ± 0.5 mm, 
p<0.001). The mean intracranial volumes were 1706 mL ± 200 mL in EPM1 patients (n=60) 
and 1949 mL ± 185 mL in controls (n=28) (p< 0.001). 
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Table 6. Cranial bone thicknesses (mm) in 66 EPM1 patients and 50 control subjects. 
 Men Women 
 Patients Controls Patients Controls 
Frontal bone 12.2 ± 2.7*** 6.8 ± 1.5 10.4 ± 3.4*** 6.3 ± 1.9 
Parietal bone 9.9 ± 2.2 *** 7.5 ± 1.4 8.9 ± 2.2 *** 6.7 ± 1.8 
Temporal bone  2.5 ± 0.8 *** 1.7 ± 0.5 2.4 ± 0.8 *** 1.5 ± 0.4 
Occipital bone 7.0 ± 1.8* 5.9 ± 1.6 6.2 ± 1.6 *** 4.8 ± 1.3 
External sagittal skull 184.8 ± 8.3 181.9 ± 8.3 178.1 ± 7.7 176.2 ± 6.9 
Internal sagittal skull 165.4 ± 8.0 164.3 ± 8.5 159.6 ± 7.3 159.7 ± 6.0 
External coronal skull 139.7 ± 5.5 140.0 ± 4.7 133.0 ± 4.7 134.6 ± 5.7 
Internal coronal skull 125.4 ± 5.1** 129.9 ± 5.0 119.9 ± 5.7 *** 125.3 ± 5.1 
External CC skull 90.2 ± 4.6* 92.9 ± 5.3 85.5 ± 4.1 86.5 ± 3.8 
Internal CC skull 81.5 ± 4.2*** 86.1 ± 4.8 79.1 ± 4.1* 81.4 ± 3.4 
Mean skull thickness 10.6 ± 1.9*** 8.0 ± 1.2 9.4 ± 2.0*** 7.2 ± 1.2 
* p ≤ 0.05 ** p ≤ 0.01 *** p ≤ 0.001 compared to control group 
 
The difference in skull thickness between patients and controls was evident in all age 
groups (Figure 7). In addition, men had thicker skulls than women both in the healthy 
control group (8.0 ± 1.2 mm vs. 7.2 ± 1.2 mm, p=0.012) and in the group of patients with 
EPM1 (10.6 ± 1.9 mm vs. 9.4 ± 2.0 mm, p=0.023). The thickness of the skull increased with 
age in EPM1 patients (r=0.363, p=0.003) but not in healthy controls (r=0.160, p=0.268) 
(Figure 7). In women in the control group, the mean thickness of the frontal bone reached 
that of men in the control group as a result of aging, but this was not observed in EPM1 
patients (Figure 8). 
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Figure 7. Mean skull thickness of EPM1 patients and healthy controls. The mean skull thickness 
was determined by calculating the average of the bilateral measurements and the differences 
between the external and internal skull dimensions. The thickness of the skull increased with 
age in EPM1 patients (r = 0.363, p = 0.003) but not in healthy controls (r = 0.160, p = 
0.268). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Mean frontal bone thickness of EPM1 patients and healthy controls. The mean frontal 
bone thickness was notably higher in EPM1 patients. Also, there was a slight increase in frontal 
bone thickness in female controls, possibly indicating hyperostosis frontalis interna. 
 
Morphologically, the thickening was generalized; there were no distinct regional or focal 
findings. However, the inner table was affected in particular. Digital head CT scans were 
available for 15 patients, and evaluation of the skull indicated osteoporotic bone structure 
in the skulls of these patients (Figure 9). 
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Figure 9. Representative images showing calvarial bone structure in a 28-year-old female 
patient. A) T1-weighted and B) T2-weighted MRI images. C) Head CT scan of the same patient 
showing marked and diffuse skull thickening and decreased bone density especially in the 
frontal bones. Note also the laminar appearance of the temporoparietal calvarium (arrows). 
 
The mean skull thickness was significantly correlated with age (r=0.363, p=0.003), duration 
of the disease (r=0.430, p<0.001) and height (r=0.292, p=0.017). There was no correlation 
between the mean skull thickness and onset age (p=0.153, r=-0.381) in EPM1 patients; 
therefore, onset age was excluded from the final ANCOVA model. There was no 
significant statistical correlation between mean skull thickness and total ICV in the EPM1 
patient group (r=-0.215, p=0.099).  No significant correlation was found between the mean 
skull thickness and ICV in male EPM1 patients (r=-0.324, p=0.066). In contrast, in the 
female patients the ICV was significantly associated with the mean skull thickness (r=-
0.517, p=0.006) and was thus included in the final ANCOVA model. 
Since age is a common confounding factor that correlates strongly with duration of the 
disease and height, and since height correlates strongly with both duration of the disease 
and ICV, these parameters were excluded from the final ANCOVA model. Eventually, the 
duration of the disease and ICV were included in an analysis of covariance with gender 
and former phenytoin use as independent variables. As shown in Table 7, the adjusted 
model predicted mean skull thickness fairly well (R2=0.362, adjusted R2=0.299, p<0.001). 
The interaction between gender and former phenytoin use was not significant 
(F(1,51)=1.078, p=0.304). Gender, ICV and duration of the disease had a significant effect 
on the mean skull thickness, while former phenytoin use did not. Type III sums of squares 
showed the contribution to the prediction, with duration of the disease (ß=0.078) being the 
most effective variable followed by ICV (ß=-0.004) and gender (ß=0.748). 
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Table 7. ANCOVA results for predicting mean skull thickness. 
Factor Type III sum of 
squares 
df Mean 
Square 
F value p ß 
Corrected model 79.970 5 15.994 5.782 0.000 - 
Duration of the disease 26.479 1 26.479 9.572 0.003 0.078 
Total ICV 21.118 1 21.118 7.634 0.008 -0.004 
Gender 14.927 1 14.927 5.396 0.024 0.7481 
Former phenytoin use 0.430 1 0.430 0.155 0.695 - 
Gender* Former2 
phenytoin use 
2.983 1 2.983 1.078 0.304 - 
Error 141.085 51 2.766    
1male EPM1 patients, 2interaction effect 
(R2 = 0.362, adjusted R2=0.299) 
 
Table 8 summarizes the structural findings determined by examining the X-ray files. 
Skeletal changes were observed in 37 (61%) EPM1 patients. Thoracic (35%) and lumbar 
spine (35%) scoliosis was common in the EPM1 patient group. Accessory ossicles of the 
foot were also recorded, and the presence of os tibiale externum (68%) was remarkably 
high. Large paranasal sinuses (27%) were another common finding. Four patients had 
arachnodactyly. 
 
Table 8. Prevalence of bone abnormalities on X-rays. 
Prevalence in our data Prevalence in literature 
 Patients  
(n) 
Percentage 
(%) 
Reference Percentage 
(%) 
Scoliosis 
Thoracic Spine 15/43 34.9 Ueno et al. 2011 (children) 1.0 
Lumbar Spine 7/20 35.0 Carter et al. 1987 (25–74 
years) 
8.3 
   Hong et al. 2010 (>60 years) 35.5 
Accessory ossicles in lower extremities 
Os tibiale 
externum 
19/28 67.9 Mellado et al. 2003  4.0-21.0 
Os peroneum 6/28 21.4 Mellado et al. 2003  9.0 
Other  6/39 15.4   
Other 
Large paranasal 
sinuses 
8/27 29.6   
Arachnodactyly 4/22 18.2   
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Furthermore, 13 patients had some other bone abnormality, including talonavicular 
coalition (n=1/29 cases in which the evaluation was possible), talocalcaneal coalition 
(n=1/29), abnormal femur angle (n=1/11), abnormal distal head of the humerus (n=1/10), 
abnormal metaphysis of the humerus (n=1/10), several exotoses in the tibia, talus and 
hallux (n=1/18), Erlenmeyer flask deformity in the femur (n=1/24), positive metacarpal sign 
(n=2/22), tapering occipital bone (n=1/15), double promontorium and extra sacral 
hemivertebrae S1 (n=1/20), hemivertebrae in the upper thoracic spine (n=1/43), apophysis 
in the lumbar vertebrae L1 and L5 (n=1/20) and Klippel-Feil fusion in the cervical spine 
(anterior segments of C2-5 and C3-4 in posterior segments) (n=1/18).  
There was a correlation between the number of bone abnormalities and the mean skull 
thickness in patients with EPM1 (r=0.427, p=0.006). No correlation was found between the 
number of bone abnormalities and patient age, duration of the disease or age of onset. 
Further, there was no difference in the number of bone abnormalities in men vs. women or 
former phenytoin users vs. non-users.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Mean skull thicknesses of former phenytoin users (n=19) and non-users (n=43) 
showed that former phenytoin use did not increase the skull thickness in EPM1 patients. 
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Figure 11. Representative images of skeletal findings in EPM1 patients. A) Os tibiale externum 
of a 47-year-old male patient. B) Arachnodactyly (MCI=10.4) of a 25-year-old female patient. 
C) Lumbar spine scoliosis of a 47-year-old male patient. D) Thoracic spine scoliosis of a 21-
year-old male patient. E) Large paranasal sinuses of a 23-year-old male patient. 
 
 
4.4 DISCUSSION 
EPM1 is a rare disorder, and clinical research has been challenging because of the small 
number of cases worldwide. Consequently, there are few imaging studies of EPM1 
patients. In the present study we had a unique opportunity to analyze the skeletal findings 
of 66 EPM1 patients. Here we report radiological findings of skeletal involvement in EPM1 
that support a role for the CSTB protein as a modulator of bone metabolism.  
EPM1 patients exhibited significant calvarial thickening in all measured cranial bones 
compared to the control group. The thickening was diffuse, involving the entire skull, and 
was most evident in the frontal, temporal and parietal bones. The skull thickness increased 
with age in EPM1 patients but not in healthy controls (Figure 7), suggesting that a lack of 
functional CSTB protein due to mutations in the CSTB gene affects the skeletal system 
throughout the patient’s lifetime. A retrospective clinical study of 20 EPM1 patients 
demonstrated that the neurological symptoms in Unverricht-Lundborg disease progress 
over a limited period, with age-related apoptosis in selected neuronal populations 
(Magaudda et al. 2006). More experimental studies are needed to better understand CSTB 
protein function in human neuronal and skeletal systems. 
It was suggested previously that hyperostosis frontalis interna (HFI) could explain the 
frontal bone thickening observed in EPM1 (Korja et al. 2007a). HFI is a sex- and age-
dependent phenomenon of unknown etiology that is highly related to the hormonal 
changes that vary over a lifetime (Hershkovitz et al. 1999, Ross, Jantz & McCormick 1998). 
The overall prevalence of HFI is 5–12%, but it is notably higher among post-menopausal 
elderly women (40–60%). HFI was also seen in our group of healthy female controls 
(Figure 8). HFI is a general incidental finding that by itself does not cause significant 
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clinical disease (Hershkovitz et al. 1999). Accordingly, HFI can be considered as a separate, 
non-disease-related phenomenon. Our results confirm more generalized skull thickening 
in EPM1 patients that cannot be explained by HFI. 
Human skull and cranial thickness have been investigated extensively. Early 
anthropological studies suggested that men have thicker skulls because of the size 
difference between men and women, but modern autopsy biopsy studies and one MRI 
study found no correlation between age, gender and body composition and thickness of 
the skull (excluding HFI) (Hershkovitz et al. 1999, Ross, Jantz & McCormick 1998, 
Hatipoglu et al. 2008, Lynnerup, Astrup & Sejrsen 2005). Contrary to these earlier studies, 
the men in our study tended to have thicker skulls than the women. The discrepancy 
between our results and those reported by others could be that we used different methods. 
Also, we used more measurement points, as well as more precise measurement points, 
than the previous studies. 
Thickening of the skull is associated with many disorders, such as severe anemia, 
polycythemia vera, myelofibrosis, hyperparathyroidism and myeloproliferative diseases 
such as lymphoma, multiple myeloma and myelodysplasic syndromes (Ghanem et al. 
2006, Nobauer, Uffmann 2005). These conditions were ruled out in our EPM1 patients. In 
addition, generalized thickening of the skull is associated with the use of an established 
anticonvulsant, phenytoin (Kattan 1970). A recent report describes skull thickening and 
cerebral atrophy after 13 years of phenytoin use (Chow, Szeto 2007). Indeed, 3 decades ago 
phenytoin was commonly used to treat epilepsy in Finland. We therefore evaluated 
whether the duration of phenytoin therapy correlated with skull thickness. Only two 
EPM1 patients had a history of long-term phenytoin therapy (≥10 years), while others 
reported short-term phenytoin use that ranged from one dose for status epilepticus up to 2 
years. In this study, previous phenytoin use did not explain the skull thickening we 
observed in EPM1 patients (Table 7 and Figure 10).  
Diffuse skull thickening and other skeletal changes are associated with a number of 
hereditary congenital bone disorders (Table 9). Interestingly, many of these disorders have 
neurological aspects, and many are extremely rare and occur only in certain populations, 
such as sclerosteosis among the Dutch settlers in Africa (Gardner et al. 2005). The genetic 
defects underlying many such disorders have been identified. For example, the role of 
cathepsin K in osteoclast function was discovered because of its association with 
pycnodysostosis (Gelb et al. 1996). Paget's disease is relatively common, and should be 
kept in mind when making a differential diagnosis of skull thickening. However, Paget's 
disease has a different clinical picture than EPM1, occurring in middle age (3–4% of those 
>40 years of age); in contrast, in EPM1 the thickening of the skull and other radiological 
findings are seen in all age groups. 
Of the 61 EPM1 patients, 37 exhibited various bone abnormalities that were noted 
during a systematic evaluation of bone X-rays (Table 8, Figure 11). In EPM1 patients, the 
prevalence of both thoracic and lumbar spine scoliosis was 35%, which is a higher 
prevalence than in healthy age-matched subjects. The literature reports prevalence rates 
for scoliosis that vary from 1% among school children (Ueno et al. 2011), to 8.3% among 
US adults aged 25–74 years (Carter, Haynes 1987) and up to 35.5% among individuals 
older than 60 years (Hong et al. 2010). Scoliosis is also widespread in patients affected by 
the syndromes shown in Table 9. Large paranasal sinuses were observed in 27% of the 
EPM1 patients, a finding that is also reported in Dyke-Davidoff-Masson syndrome (Atalar, 
Icagasioglu & Tas 2007) (Table 9). Accessory ossicles of the foot were relatively common in 
the EPM1 patients, and the prevalence of os tibiale externum was remarkably high (68%) 
among EPM1 patients compared to the estimated prevalence of 4–21% in healthy 
individuals (Mellado et al. 2003). In addition, the EPM1 patients exhibited arachnodactyly, 
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vertebral abnormalities and other occasional bone findings.  
The main limitation of the current study was its retrospective design. All patients 
prospectively underwent head MRI, but bone structure evaluation was limited to the 
clinical X-ray files that were available in the patients’ medical files. Systematic prospective 
evaluation of skeletal changes in EPM1 patients was not possible due to radiation 
exposure concerns. However, there was a correlation between the number of bone 
abnormalities and the mean skull thickness in individual EPM1 patients; this correlation 
may have been statistically underestimated because the number of available x-ray files 
varied among the patients, and this may have influenced which skeletal changes we 
observed. Further, EPM1 patients may have more bone fractures than the healthy 
population. Traumatic skeletal changes were not evaluated in the present study. An excess 
of fractures could theoretically be associated with the movement disorder and epilepsy, as 
well as with the immobilization and reduced bone mineral density (Beerhorst et al. 2012). 
Unfortunately, EPM1 patients did not undergo bone mineral density measurements and 
bone turnover markers were not determined, which is a limitation of our study. These 
would have afforded more detailed information about the nature and severity of fractures, 
bone mass and bone mineral density in the patients with EPM1. 
CSTB is an endogenous inhibitor of cysteine cathepsins, which are lysosomal proteases 
that promote apoptosis (Green et al. 1984, Leist, Jaattela 2001). Experiments show that 
CSTB has neuroprotective properties and that cathepsin B contributes to the 
pathophysiology of EPM1 (Pennacchio et al. 1998, Shannon et al. 2002, Houseweart et al. 
2003, Lehtinen et al. 2009). Cathepsin K, a major cysteine protease in mature osteoclasts, 
has a critical role in bone resorption (Gelb et al. 1996, Saftig et al. 1998, Xia et al. 1999). In 
vitro study shows that CSTB is involved in bone resorption by regulating intracellular 
cathepsin K activity and that it protects osteoclasts from experimentally-induced apoptosis 
(Laitala-Leinonen et al. 2006). In mice, overexpression of cathepsin K increases the 
thickness and mineral density of diaphyseal cortical bone and increases the porosity of the 
diaphyseal cortex (Morko et al. 2005). In line with these findings, osteoporotic structures 
were observed in the head CT scans of the EPM1 patients in this study (Figure 9). Taken 
together, these data support the idea that a decrease in functional CSTB contributes to the 
skeletal phenotype of EPM1. 
It has been shown that also human osteoblasts produce cathepsin K in vitro and the 
osteoblast-like cells function as matrix-degrading cells and can finalize the resorption 
phase before synthesizing new mineralized matrix (Mandelin et al. 2006, Mulari et al. 
2004). Pycnodysostosis is a genetic deficiency of cathepsin K characterized by short 
stature, brittle bones and increased bone density. Contrary to these findings, delayed 
calvarial ossification and acro-osteolysis are also seen in pycnodysostosis  (Gelb et al. 
1996). This could be explained by the fact that the ossification of the human skull and the 
distal phalanges greatly differs from other skeletal structures. Further, impaired 
osteoclastic bone resorption in cathepsin-K-deficient mice results in the activation of 
osteoblastic cells to produce increased amounts of proteolytic enzymes in vivo (Kiviranta et 
al. 2005), and the overexpression of cathepsin K accelerates the resorption cycle and 
osteoblast differentiation (Morko et al. 2009). The detailed nature of cathepsin K activation 
is still poorly known and further studies are warranted to investigate whether osteoblastic 
cathepsin K has consequences in pycnodysostosis or the skeletal changes seen on EPM1 
patients. 
Loss of neurons plays a critical role in the pathophysiology of EPM1. From 2 months of 
age onwards, CSTB-deficient mice exhibit a severe loss of cerebellar granule cells as well 
as marked progressive loss of cerebellar volume and progressive atrophy of the cerebral 
cortex (Pennacchio et al. 1998, Tegelberg et al. 2012). Moreover, early and localized glial 
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activation precedes neuron loss, which first occurs within the cortex in the thalamocortical 
system and, subsequently, in the corresponding thalamic relay nucleus (Tegelberg et al. 
2012). In addition, imaging studies in human EPM1 patients show mild to moderate 
cerebral and cerebellar atrophy in visual assessment, an MRI study shows loss of neuronal 
volume in the brainstem and motor cortex, and a VBM study shows thalamic atrophy 
(Koskenkorva et al. 2009, Chew et al. 2008, Mascalchi et al. 2002, Santoshkumar, Turnbull 
& Minassian 2008). In light of these findings, in the present study we hypothesized that 
thicker skulls would correspond to smaller brains. However, there was no significant 
statistical correlation between mean skull thickness and total ICV in the EPM1 patient 
group. The ANCOVA model (Table 7) showed a statistical correlation between ICV and 
mean skull thickness (p=0.008), but the regression coefficient for ICV as a predictor of 
mean skull thickness was small (β=-0.004). This may be because EPM1 selectively targets 
specific cells in certain brain structures while most of the neuronal architecture remains 
intact.  
In conclusion, skull thickening and other specific skeletal findings in 66 EPM1 patients 
suggested that abnormal ossification of the skeleton is a universal feature of EPM1 that is 
associated with a defect in CSTB function. In order to gain a more complete understanding 
of the skeletal phenotype in EPM1, prospective evaluations of skeletal development, bone 
mineral density and fracture healing are required, as is molecular characterization of CSTB 
function in osteoclasts. 
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5 Regional cortical thinning associates with 
neurocognitive profile in Unverricht-Lundborg disease 
(EPM1) 
ABSTRACT  
 
Objectives 
Patients with Unverricht-Lundborg disease (progressive myoclonus epilepsy type 1, 
EPM1) display considerable variation in both clinical severity and neurocognitive 
manifestations even though they have a uniform genotype. Cortical thickness analysis 
(CTH) in MRI provides group-level structural information in neurological and 
neuropsychological disorders. The aim was to investigate the possible relationship 
between cortical thickness, disease severity and neurocognitive function in EPM1. 
 
Methods 
Sixty-three genetically verified EPM1 patients were clinically evaluated by using the 
Unified Myoclonus Rating Scale (UMRS) test panel. Patients were divided into three sub-
groups according to their myoclonus in action score: Mild Disability (Action myoclonus 
scores 1−30; n=20); Moderate Disability (scores 31−59, n=21) and Severe Disability (scores ≥ 
60; n=22). The cognitive performance of the patients was evaluated with a 
neuropsychological test battery, tailored to be suitable for EPM1. The patients underwent 
T1-weighted 3-dimensional MR imaging. The regional cortical thicknesses (CTH) were 
analysed and correlated to the neurocognitive profile.  
 
Results 
Intellectual functioning of the patients varied from high average to defective and 
correlated with the disease severity. Utilizing the CTH analysis, the EPM1 patients with 
the severe form of the disease had thinner cortex than patients with a milder form of the 
disease. The anatomical areas affected included Broca’s and Wernicke’s areas; fusiform 
gyrus; retrosplenial and perirhinal cortex (areas responsible for processing of verbal and 
complex visual data) and posterior cingulate and anterior prefrontal cortex (areas 
responsible for higher-order cognitive functions). 
 
Conclusions 
CTH analysis can supplement new information on visually normal MR images. The 
observed associations provide a structural neuroanatomical-biological basis for disease 
severity and cognitive decline in EPM1. A further evaluation will be needed to clarify the 
benefits of assessing CTH in individual EPM1 patients. 
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5.1 INTRODUCTION 
Unverricht-Lundborg disease, progressive myoclonus epilepsy type 1 (EPM1, OMIM 
254800) (Shahwan, Farrell & Delanty 2005) is a rare neurodegenerative disorder caused by 
mutations in the cystatin B encoding CSTB gene (Pennacchio et al. 1996, Lalioti et al. 1997, 
Joensuu, Lehesjoki & Kopra 2008). The age of onset in EPM1 is usually between 6–16 years 
and the first symptoms are stimulus-sensitive myoclonic jerks and tonic-clonic epileptic 
seizures. During the subsequent 5–10 years, symptoms progressively worsen and patients 
develop ataxia, intentional tremor, dysarthia and other signs of motor incoordination. 
Devastating myoclonias are the most disabling symptoms encountered during the disease. 
However, the clinical course and phenotype of the disease are heterogeneous. (Kälviäinen 
et al. 2008) 
Cognitive function in patients with EPM1 has been found to be impaired, e.g., deficits 
in processing and executive functions and in working memory have been reported (Chew 
et al. 2008, Ferlazzo et al. 2009, Giovagnoli et al. 2009). Psychiatric disorders have been also 
described (Magaudda et al. 2006, Chew et al. 2008, Ferlazzo et al. 2009) although the 
presence of psychiatric problems in EPM1 has not been systematically assessed. 
At the time of the EPM1 diagnosis, the qualitative MRI of the brain is usually 
interpreted as normal (Kälviäinen et al. 2008). However, volumetric/statistical analysis of 
the MR images of patients with EPM1 has revealed cerebral atrophy (Koskenkorva et al. 
2009, Mascalchi et al. 2002). A previous cortical thickness analysis (CTH) study detected 
significant thinning of the cortical motor areas of patients with EPM1 and this was linked 
to the degree of the clinical severity of the myoclonus (Koskenkorva et al. 2012). CTH is a 
novel MR image analysis method that has been proposed to be a more sophisticated 
alternative to volumetric and voxel-based morphometry methods for measuring regional 
brain atrophy since it provides a direct quantitative index of regional thickness of the 
cerebral cortex (Lerch, Evans 2005, Lerch et al. 2005). 
It is not understood why there are such wide clinical and neurocognitive variations in 
patients with EPM1 i.e. the heterogeneity of the phenotype. Though the primary genetic 
defect mutation in EPM1 is known, the actual pathological mechanisms leading to the 
symptoms remain unclear. By combining structural MRI data of the regional thickness of 
the cerebral cortex and quantitative results from neuropsychological evaluation, we aimed 
to determine whether cortical structures in specific brain areas could be linked to the 
cognitive impairments of the EPM1 patients. 
 
 
5.2 PATIENTS AND METHODS 
5.2.1 Subjects 
Sixty-three genetically verified patients with EPM1 (35 men, 28 women; mean age 35.1 ± 
10.9 years, range 16−64 years) participated a translational clinical and molecular genetics 
study organized by Kuopio Epilepsy Center, Kuopio University Hospital jointly with the 
Folkhälsan Institute of Genetics and Neuroscience Center, University of Helsinki; the 
patients were evaluated in 2006−2010. The ethical committee of Kuopio University 
Hospital approved the study protocol, and a written informed consent was obtained from 
all participants. 
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5.2.2 Clinical assessment of EPM1 patients 
A neurologist performed the clinical evaluations. The medical histories of EPM1 patients 
were collected from medical records and by interviewing the patients and their relatives. 
EPM1 patients’ clinical data is presented in Table 11. At the time of imaging and 
neuropsychological examination, all patients were treated with antiepileptic drugs 
(AEDs). The patients typically received a combination of at least two AEDs, titrated 
individually to maximally tolerated dosages (Table 10). With the exception of the oldest 
patient, all other 62 patients were receiving valproate. One patient had valproate acid 
monotherapy, 13 patients were being treated with 2 AEDs, 23 patients with 3 AEDs, 17 
patients with 4 AED’s, 8 patients with 5 AED’s and 1 patient with 6 AED’s. 
The severity of myoclonus was used as a criterion for different subgroups, as the 
clearest marker of the disease progression. The Unified Myoclonus Rating Scale (UMRS) 
test panel was used for myoclonus severity evaluation as a part of the clinical examination. 
UMRS is a quantitative 74-item clinical rating instrument comprising 8 sections (Frucht et 
al. 2002). Patients’ performances were recorded on video and the test sections were 
evaluated using a standard protocol. Myoclonus with action score (1−160) was used to 
evaluate the severity of myoclonus. The patients were subsequently classified into three 
disability groups according to the Myoclonus with Action scores:  Mild Disability Group 
had scores 1−30; Moderate Disability Group had scores 31−59 and Severe Disability Group 
had scores ≥ 60. 
 
Table 10. AEDs and dosages of patients with EPM1 received at time of 
neuropsychological testing. 
Medication (mg/day) n Mean ± SD Range 
Valproate  62 1600 ± 650 300 – 3500 
Clonazepam 49 4.4 ± 2.7 0.25 – 12 
Levetiracetam 44 2290 ± 990 500 – 4000 
Topimarate 14 270 ± 240 75 – 1000 
Lamotrigine 12 210 ± 110 25 – 400 
Piracetam 10 13680 ± 8060 2400 – 24000 
Clobazam 3 30 ± 15 10 – 40 
Other* 16   
*phenobarbital, pirimidone, zonisamide, diapam, nitrazepam, ethasuximide 
 
5.2.3 Neuropsychological evaluation 
Described in detail by Äikiä et al. (unpublished data), the neuropsychological evaluation 
consisted of measures for intellectual ability, verbal memory as well executive and 
psychomotor functions. Intellectual ability was assessed with six subtests of the Wechsler 
Adult Intelligence Scale Revised (WAIS-R) (Wechsler D 1981). Verbal and Performance 
Intelligence Quotients (VIQ and PIQ) were calculated. Verbal memory was assessed with a 
15-word list learning test and story recall test, immediate and delayed memory were 
evaluated and percent retention scores were calculated. Executive functions were assessed 
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with the Trail Making test (TMT) and Stroop test. Psychomotor function was evaluated 
with Digit symbol test, alternating S-task and finger tapping. The neuropsychological test 
variables were converted into z-scores relative to the control group mean. 
5.2.4 MR Imaging Acquisition Protocol and Data Analysis 
The MR (1.5 T, Siemens Avanto, Erlangen, Germany) imaging protocol included T1- and 
T2- weighted and fluid attenuated inversion recovery sequences, and T1- weighted 3D 
images (magnetization-prepared rapid acquisition of gradient echo: TR 1980 ms, TE 3.09 
ms, flip angle 15°, matrix 256 x 256, 176 sagittal sections with section thickness varying 
between 1.0 and 1.2 mm depending on the size of the head; in-slice resolution of 1.0 mm x 
1.0 mm). A neuroradiologist (P.K) assessed all conventional images visually for focal 
abnormalities. 
5.2.5 CTH analysis 
CTH analysis was conducted by using the pipelining method developed in the McConnell 
Brain Imaging Centre, Montreal Neurologic Institute, McGill University, Montreal, 
Canada (http://www2.bic.mni.mcgill.ca/). First, the individual MR image volumes were 
spatially normalized to the standard template (Mazziotta et al. 2001), intensity 
inhomogeneities were corrected with the N3 algorithm (Sled, Zijdenbos & Evans 1998) and 
extracerebral voxels were removed with a stereotactic brain mask (Smith 2002). Then, the 
magnitude of the partial volume effect was estimated for each voxel (Tohka, Zijdenbos & 
Evans 2004) and brain tissue was divided into gray matter (GM), white matter (WM), and 
cerebrospinal fluid (CSF) by using the intensity-normalized stereotactic environment for 
classification of tissues (INSECT) algorithm (Zijdenbos 1998). The brains were 
automatically divided into two separate hemispheres and the inner and outer surfaces of 
the cortex were extracted by using the constrained Laplacian-based automated 
segmentation with a proximities (CLASP) algorithm (Kim et al. 2005) followed by 
identification of white matter surface (WMS) i.e. the surface between WM and GM, and 
gray matter surface (GMS) i.e. the surface between GM and CSF. First, CLASP formed the 
inner surface by expanding an ellipsoid polygon mesh to the shape of the WMS. GMS was 
modelled by further expanding the inner surface. The thickness of the cortex was defined 
with a t-link metric at each linked node as the distance between WMS and GMS and as a 
result a CTH map of 40,962 nodes per hemisphere was acquired (Lerch, Evans 2005). The 
thickness calculations were performed on each subject’s native space and were then 
transformed back to the standard space for the group analysis. Finally, the data were 
smoothed with a 20-mm full width at half maximum diffusion smoothing kernel to 
improve the signal-to-noise ratio and statistical power (Chung, Taylor 2004).  
 
5.2.6 Statistical analysis 
Statistical analyses of CTH were performed according to the general linear model with 
Matlab R2007b (The MathWorks Inc., Natick, MA). Differences between Mild, Moderate 
and Severe Disability groups were tested by using a t test (p < 0.05), corrected for multiple 
comparisons with the FDR method. The correlations between the CTH values and the z-
scores of the neuropsychological tests were tested in each node for all patients as one 
group. Correlations were calculated for the following neuropsychological variables: PIQ, 
VIQ; immediate and delayed verbal memory scores (six scores); executive function: (TMT, 
Stroop); and psychomotor function (alternating S-task, Digit symbol and finger tapping). 
Patients with missing test scores were excluded from the specific correlation analysis. In 
all CTH analysis, gender was used as a nuisance variable. As the age of the patient 
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significantly correlates with the duration of the disease, and the duration of the disease 
correlates with the clinical severity of the symptoms, age was not used as a nuisance 
variable. However, it has been shown that although age correlates negatively with CTH in 
both patients and controls, the cortical thinning follows regionally a more limited pattern 
in patients with EPM1 in comparison with healthy controls (Koskenkorva et al. 2012). 
Other statistical analyses shown in Table 11 were performed with the statistical 
software SPSS 19.0 for Windows (IBM SPSS Inc., Chigaco, IL). Mann-Whitney U test was 
used to assess differences in clinical and demographical variables. Differences were 
considered statistically significant when p <0.05. 
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5.3 RESULTS 
Demographic and clinical data of the EPM1 patients are presented in Table 11. When 
assessed visually, no focal signal intensity abnormalities were found in the conventional 
MR images.  
5.3.1 Cortical thickness and disease severity 
The Severe Disability Group had statistically significantly thinner cortex values than the 
Mild Disability Group (Figure 12). In the regional analysis, widespread cortical thinning 
was observed in the primary and secondary visual cortices (BA17 &18), associative visual 
cortex (BA19), primary auditory and auditory association cortex (BA41 & 42), Broca’s area 
i.e. pars opercularis (BA44) and pars triangularis (BA45), parts of Wernicke’s area (BA22, 
39 & 40), piriform cortex (BA27), fusiform gyrus (BA37), parts of primary gustatory cortex 
(BA43) and parts of posterior cingulate cortex (BA23 & 31). Retrosplenial regions of the 
cerebral cortex (BA26, 29, 30), perirhinal cortex (BA35), parts of primary somatosensory 
cortex (BA1 & 2) and primary motor cortex (BA4) displayed thinning particularly in the 
right but also on the left hemisphere. In addition, parts of the prefrontal cortex (BA9, 10 & 
11) were affected. There was also thinning of the somatosensory association cortex (BA5) 
and posterior entorhinal cortex (BA28) in the left hemisphere.  
No statistically significant differences in CTH were found in comparisons between 
Moderate and Severe Disability Groups or between the Mild and Moderate Disability 
Groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Statistical differences (p 
< 0.05, FDR corrected) in cortical 
thickness between Mild Disability 
Group and Severe Disability Group 
patients with EPM1. Severe 
Disability Group exhibits 
widespread cortical thinning 
compared to the Mild Disability 
Group. 
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5.3.2 Correlations between cortical thickness and neuropsychological test scores 
In the correlation analysis between CTH and neuropsychological test scores, all the EPM1 
patients were treated as one group. Test results of finger tapping and alternating S-task 
showed a significant positive correlation with CTH. The results of the correlation analyses 
are presented in Table 12 and illustrated in Figure 13 with respect to the finger tapping 
and in Figure 14 for the alternating S-task. PIQ, VIQ, Digit symbol and Verbal memory 
and Executive function tests did not reveal any significant correlation with cortical 
thickness in EPM1 patients. 
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Table 12. Cortical areas in the right and left hemisphere correlating with the finger-tapping and 
alternating S task z-scores. 
Neuropsychological 
test 
Regions of correlations in the right 
hemisphere 
Regions of correlations in the left 
hemisphere 
Finger-tapping 
(Figure 13) 
A part of primary somatosensory 
cortex (BA2) 
 
  
A small part of somatosensory 
association cortex (BA5) 
 Frontal eye fields (BA8) Frontal eye fields (BA8) 
 
A small part of frontopolar cortex 
(BA10) 
Frontopolar cortex (BA10) 
 A part of orbitofrontal cortex (BA11)  
 
Parts of secondary visual cortex 
(BA18) 
 
 
Small parts of superior temporal area 
(BA22) 
Small parts of Wernicke’s area (BA22) 
 
Parts of posterior cingulate cortex 
(BA23 & 31) 
Parts of posterior cingulate cortex (BA23 
& 31) 
 Retrosplenial cortex (BA26, 29, 30) 
Parts of retrosplenial cortex (BA26, 29, 
30) 
 Piriform cortex (BA27)  
 Perirhinal cortex (BA35) Perirhinal cortex (BA35) 
 
Primary auditory and auditory 
association cortex (BA41 & 42)  
Primary auditory and auditory 
association cortex (BA41 & 42) 
 Parts of pars opercularis (BA44) A part of Broca’s area (BA44 & 45) 
  Parts of orbitofrontal cortex (BA 47) 
Alternating S task 
(Figure 14) 
A small part of primary somatosensory 
cortex (BA2, superior postcentral 
sulcus) 
 
  A small part of frontal eye fields ( BA 8) 
 Primary visual cortex (BA17) Parts of primary visual cortex (BA17) 
 
Parts of secondary visual cortex 
(BA18) 
Parts of secondary visual cortex (BA18) 
 
A small part of superior temporal area 
(BA22) 
A small part of Wernicke’s area (BA22) 
 Retrosplenial cortex (BA26, 29, 30)  
 Perirhinal cortex (BA35)  
  Parts of Broca’s area  (BA44, 45) 
BA = Brodmann area 
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Figure 13. Correlation between cortical thickness and performance in finger-tapping test in 
patients with EPM1 (n=57). CTH and Z-scores of finger-tapping test were positively correlated 
(p < 0.05, FDR corrected). 
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Figure 14. Correlation between cortical thickness and performance in alternating S-task in 
patients with EPM1 (n=55). CTH and Z-scores of alternating S-task were positively correlated 
(p < 0.05, FDR corrected). 
 
 
5.4 DISCUSSION 
 
This study indicates that there is a structural background to the neurocognitive decline 
experienced by the patients with EPM1. The phenotype of our patients is carefully 
described by Hyppönen et al. including comprehensive clinical findings of the Finnish 
patients with EPM1 (unpublished data). The main neuropsychological findings of the 
patients have been described by Äikiä et al. (unpublished data). The subjects with a severe 
phenotype displayed extensive thinning in several cortical areas; areas that are considered 
important in higher-level cognitive functions. Previous studies have revealed that the 
decline in cognitive function in patients with EPM1 occurred in parallel with the extent of 
general disability however with significant individual variation (Chew et al. 2008, Ferlazzo 
et al. 2009, Giovagnoli et al. 2009). This is the first study to describe an association between 
a local structural damage and cognitive impairment in EPM1. CTH was able to reveal mild 
cortical atrophy, not visible on conventional visual assessment of brain MRI; these 
pathological disturbances may explain the subnormal performance of the patients in 
various neuropsychological tasks.  
5.4.1 Areas of cortical thinning in severe form of EPM1 
Studies with modern group-level neuroimaging methods have been able to reveal gray 
matter volume reduction and diffuse cortical thinning particularly in the motor, sensory, 
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visual and auditory cortices (Koskenkorva et al. 2009, Koskenkorva et al. 2012). In our 
study, the subgroup of EPM1 patients with the severe form of disease displayed 
widespread thinning of the cerebral cortex in comparison with the subgroup with only 
mild disability; the sensory, visual and auditory cortices were the areas most severely 
affected (Fig. 12). In addition, brain regions for language functions (i.e., Broca’s and 
Wernicke’s areas) were thinner in patients with more severe EPM1. The cortical thinning 
present in the Broca’s area could at least partly account for the development of dysarthria 
which typically is encountered some years after the diagnosis. 
The retrosplenial cortex was thinner particularly in the right hemisphere in the severe 
EPM1 subgroup. The retrosplenial cortex (BA26, 29, 30) projecting to the anterior thalamic 
nuclei and hippocampus is involved in episodic and spatial memory, navigation, 
imagination and planning for the future (Vann, Aggleton & Maguire 2009). 
Neurocognitive studies and case reports have indicated that patients with damaged 
retrosplenial cortex suffer spatial orientation deficits and experience difficulty in acquiring 
new visual information (Maguire 2001). The posterior cingulate cortex was also thinner in 
patients with severe EPM1. The posterior cingulate cortex (BA23, 31) is a part of the 
default mode network, a set of brain regions that are highly active during rest, and it is 
believed to generate spontaneous thoughts during mind-wandering (Buckner, Andrews-
Hanna & Schacter 2008). 
Posterior parts of perirhinal cortex (BA35) were bilaterally thinner in patients with 
severe EPM1. The perirhinal cortex contributes to higher-order visual perception and 
complex conjunctions of objects and storage of visual data in the memory (Murray, Bussey 
& Saksida 2007). The fusiform gyrus (BA37) was bilaterally thinner in patients with more 
severe EPM1. The fusiform gyrus is known to be involved in the perception of faces 
(Kanwisher, McDermott & Chun 1997) but it also has highly selective neural populations 
for recognition of non-facial objects (Grill-Spector, Sayres & Ress 2006). The piriform 
cortex (BA27) was bilaterally thinner in patients with severe EPM1. The piriform cortex is 
a highly seizure-prone region (Piredda, Gale 1985).  
 
5.4.2 Anatomical correlates of distinct neuropsychological test results 
Correlations were found between psychomotor function test scores (finger tapping and 
alternating S-task) and the thickness of cortical areas that process visual data: Finger 
tapping correlated positively with the CTH especially in areas involved in higher-order 
visual perception as previously mentioned (BA26, 29, 30, 35) and also with frontal eye 
fields (BA8). The performance scores in Finger tapping correlated also with the CTH in 
prefrontal cortex: frontopolar cortex (BA10) particularly on the left; and orbitofrontal 
cortex on the right (BA11) and left (BA47) (Figure 13). In addition to motor functions, the 
frontopolar cortex is involved in the executive system including decision making 
(Koechlin, Hyafil 2007, Ramnani, Owen 2004). Furthermore, orbitofrontal cortex is thought 
to be involved in decision making, expected reward situations and associative learning 
(Schoenbaum et al. 2011).  
We did not detect any statistically significant correlations in cortical thickness with 
other cognitive measures such as verbal memory or executive function parameters. This 
may be due to the fact that several patients with severe disability could not perform the 
executive function tests and had to be excluded from these analyses. There were also no 
correlations found between cortical thickness and PIQ and VIQ which is to be expected 
due to the complex nature of these cognitive measures. In general, the statistical 
significance of CTH analyses requires a reasonably large group size and/or a 
homogeneous group. Since the EPM1 patient group is rather heterogeneous with regards 
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to the severity of the symptoms, the reduction in group size due to missing test scores 
might have affected the statistical significance and reduced to some extent the reliability of 
the results.  
It has to be stressed that in EPM1 patients the structural alterations are restricted not 
only to cerebral cortex but also extend to deep gray matter and white matter (Koskenkorva 
et al. 2009, Manninen et al. 2013). Thus, the cortical findings could not be expected to 
comprehensively account for all aspects of the neurocognitive impairment experienced by 
patients with EPM1. 
The statistical analyses in our study are also complicated by the fact that the age of the 
patient, duration of the disease, clinical severity of the symptoms and CTH are all 
mutually correlated. The only way to eliminate the possible effect of age in the present 
results would have been to evaluate similar groups in terms of age, sex and duration of the 
disease but this was not possible due to the inherently small study population. However, 
it has been shown that although age correlates with CTH in both healthy controls and 
patients with EPM1, the regional distribution of thinning is more limited in EPM1 
(Koskenkorva et al. 2012). The onset of EPM1 is in early childhood or late adolescence with 
the peak occurring around 12–13 years (Genton 2010), thus the cortical areas maturing 
before and after onset may behave differently.  
Recently, a CTH study of patients with intractable focal epilepsy and childhood onset 
epilepsy detected a reduced WM and parietal lobe thickness in valproate users vs. non-
users (Pardoe, Berg & Jackson 2013). In EPM1, valproate is the drug of choice and its use is 
started as soon as the disease is diagnosed. Thus, valproate is used as the main AED 
virtually in all patients with EPM1 (Kälviäinen et al. 2008). However, a recent translational 
study detected analogous WM degeneration in Cstb-deficient (Cstb–/–) mice and patients 
with EPM1 (Manninen et al. 2013). Furthermore, neuronal loss and progressive thinning of 
the cortex are also present in Cstb-deficient mice (Tegelberg et al. 2012).  Although the 
possible effects of valproate cannot be omitted in our patient population they do not alone 
explain the cortical thinning in patients with EPM1. 
 
5.5 CONCLUSION 
The current study is the first to report associations between cortical thinning and cognitive 
functions in EPM1. Although visually interpreted MRI typically remains normal, CTH not 
only revealed abnormalities but these were also correlated to poor neuropsychological 
performance. Patients with a severe form of EPM1 have extensively thinner cortices than 
patients with a mild form of the disease. The brain areas that process verbal and complex 
visual data or those involved in higher order cognitive functions become particularly 
affected in patients with severe EPM1 providing an anatomical-biological background for 
the link between the severity of disability and cognitive decline in EPM1. The basis for the 
heterogeneity of the disease remains unclear. Future research will determine whether CTH 
analysis will prove helpful in the prognostic assessment in individual patients with EPM1 
e.g. in newly diagnosed patients. 
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6 3D texture analysis reveals imperceptible MRI 
textural alterations in the thalamus and putamen in 
progressive myoclonic epilepsy type 1, EPM1 
ABSTRACT 
 
Progressive myoclonic epilepsy type 1 (EPM1) is an autosomal recessively inherited 
neurodegenerative disorder characterized by young onset age, myoclonus and tonic-clonic 
epileptic seizures. At the time of diagnosis, the visual assessment of the brain MRI is 
usually normal, with no major changes found later. Therefore, we utilized texture analysis 
(TA) to characterize and classify the underlying properties of the affected brain tissue by 
means of 3D texture features. 
Sixteen genetically verified patients with EPM1 and 16 healthy controls were included 
in the study. TA was performed upon 3D volumes of interest that were placed bilaterally 
in the thalamus, amygdala, hippocampus, caudate nucleus and putamen.  
Compared to the healthy controls, EPM1 patients had significant textural differences 
especially in the thalamus and right putamen. The most significantly differing texture 
features included parameters that measure the complexity and heterogeneity of the tissue, 
such as the co-occurrence matrix-based entropy and angular second moment, and also the 
run-length matrix-based parameters of gray-level non-uniformity, short run emphasis and 
long run emphasis.  
This study demonstrates the usability of 3D TA for extracting additional information 
from MR images. Textural alterations which suggest complex, coarse and heterogeneous 
appearance were found bilaterally in the thalamus, supporting the previous literature on 
thalamic pathology in EPM1. The observed putamenal involvement is a novel finding. Our 
results encourage further studies on the clinical applications, feasibility, reproducibility 
and reliability of 3D TA. 
 
6.1 INTRODUCTION 
 
Progressive myoclonic epilepsy type 1 or Unverricht-Lundborg disease (EPM1, ULD, 
OMIM 254800) is the most common type of progressive myoclonic epilepsy (Shahwan, 
Farrell & Delanty 2005). It is an autosomal recessively inherited neurodegenerative 
disorder caused by mutations in the cystatin B gene (CSTB) (Pennacchio et al. 1996, Lalioti 
et al. 1997, Lafreniere et al. 1997). EPM1 in Finland has an incidence of 1:20 000 births per 
year, with about 200 diagnosed cases (Norio, Koskiniemi 1979), but it is also prevalent 
elsewhere in the Baltic Sea region and in the Western Mediterranean area. Sporadic cases 
of EPM1 have been reported worldwide (Kälviäinen et al. 2008). 
The first symptoms of EPM1 are commonly stimulus-sensitive myoclonic jerks and 
generalized tonic-clonic epileptic seizures. Neurological examination is initially normal, 
but patients later develop intention tremor, dysarthria, ataxia and poor coordination, thus 
subsequently one-third of EPM1 patients become severely incapacitated and wheelchair 
bound. Alternatively, the clinical symptoms can be so mild that there is a delay in the 
diagnosis and patients may manage well. (Kälviäinen et al. 2008) Mild cognitive 
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impairment and slow decline in intellectual level over time have been reported 
(Kälviäinen et al. 2008, Chew et al. 2008, Ferlazzo et al. 2009, Lehesjoki, Koskiniemi 1999).  
MRI findings of the patients with EPM1 remain sparse. At the time of diagnosis, MRI of 
the brain is usually normal (Kälviäinen et al. 2008). However, changes in MRI, such as 
mild to moderate cerebral and/or cerebellar atrophy, loss of neuronal volume in the 
brainstem and high intensity signal changes in the basal ganglia have been reported as 
well (Chew et al. 2008, Mascalchi et al. 2002, Santoshkumar, Turnbull & Minassian 2008, 
Korja et al. 2010). Recently modern group level MRI analysis methods have revealed loss 
of gray matter volume in cortical motor areas (voxel-based morphometry, VBM), and 
atrophy of the sensorimotor, visual and auditory cortices (cortical thickness analysis, CTH) 
in EPM1 patients (Koskenkorva et al. 2009, Koskenkorva et al. 2012) while abnormal 
findings could not be detected in visual assessments. Loss of gray matter volume in the 
thalamus has also been reported in one VBM study (Koskenkorva et al. 2009), paralleling a 
PET study indicating dopamine depletion in the thalamostriatal area in four EPM1 
patients (Korja et al. 2007b). 
Although the human visual system can discriminate different textures, the capacity of 
human vision to detect and discriminate between complex higher-order textures is limited 
(Julesz 1973). Texture analysis (TA) is a method to evaluate the position of signal features 
i.e. pixels/voxels, and their gray-level intensity, distribution and relationships in a digital 
image (Castellano et al. 2004). TA presents texture features as mathematical parameters, 
which could characterize the properties of the underlying tissue. These features can be 
described as, for example, fine, coarse, smooth, or irregular (Haralick 1973). Previously, 
texture analysis techniques have been used two-dimensionally in medical imaging of 
multiple sclerosis, brain tumours and brain injuries (Castellano et al. 2004, Holli et al. 
2010c, Kassner, Thornhill 2010). In epilepsy research, TA has been applied in temporal 
lobe epilepsy, focal cortical dysplasia and juvenile myoclonic epilepsy (JME) (Yu et al. 
2001, Bonilha et al. 2003, Jafari-Khouzani et al. 2010, Alegro et al. 2012, Antel et al. 2003, 
Bernasconi et al. 2001, de Oliveira et al. 2013).  
Theoretically, three-dimensional (3D) texture analysis provides more comprehensive 
data analysis of biological tissue texture properties and enables calculation of texture 
parameters in several directions. However, the literature on 3D TA applications in brain 
research is still sparse (Zhang et al. 2012, Kovalev, Kruggel & von Cramon 2003, 
Mahmoud-Ghoneim et al. 2003, Chen et al. 2007, Kocinski et al. 2012, Georgiadis et al. 
2009). 
Patients with EPM1 seem to provide a suitable population to assess the feasibility of 
novel image analysis techniques to detect possible subtle changes in the brain that are not 
evident upon visual assessment. The specific aim of this study is to investigate possible 
imperceptible structural differences in the thalamus and other deep gray matter tissue in 
patients with EPM1 via comparison with healthy controls by using three-dimensional 
MRI-based texture analysis. Further, we want to determine whether the possible texture 
changes correlate with EPM1 patients’ clinical symptoms and neuropsychological 
findings. 
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6.2 PATIENTS AND METHODS 
6.2.1 Subjects 
EPM1 patients were evaluated at Kuopio University Hospital during the period 2006 − 
2010. The study was jointly administered by the Folkhälsan Institute of Genetics and 
Neuroscience Center at the University of Helsinki. The patients had either participated in 
an earlier molecular genetics study or were referred to the Kuopio Epilepsy Center during 
the study. The ethics committee at the Kuopio University Hospital approved the study 
and written informed consent was obtained from all participants. 
The original EPM1 study group comprised 66 EPM1 patients. In all cases, MR images 
were obtained using a T1-weighted 3D MPRAGE sequence. Due to slight differences in 
updated scanner versions, technical difficulties, and slightly different slice thicknesses in 
some of the controls due to differences in head size, slight modifications in the parameters 
and resolutions were observed. Consequently, 16 genetically verified EPM1 patients (10 
male, mean age of 31.0 ± 10.9 years, range 18 − 51 years) and 16 healthy controls (8 men, 
mean age of 35.2 ± 12.0 years, range 19 − 52 years) shared identical MPRAGE sequence 
details and were included in the 3D TA study.  
6.2.2 Clinical assessment of patients with EPM1 
Of the EPM1 patients, 13 were homozygous for the dodecamer expansion mutation, while 
3 were compound heterozygous for the expansion mutations. The mean onset age was 9.6 
± 1.9 years (range 5 − 12 years) and the mean duration of the disorder at the time of the 
study was 21.4 ± 10.2 years (range 8 − 41 years). All of the EPM1 patients were treated with 
antiepileptic drugs (AEDs). Valproate was in use in all 16 patients and was augmented 
with levetiracetam (n = 10), clonazepam (n = 10), topimarate (n = 3) piracetam (n = 4), 
lamotrigine (n = 5), clopazam (n = 1) or other AEDs (n = 5). The medical histories of EPM1 
patients were confirmed from medical records and by interviewing the patients and their 
relatives. A Unified Myoclonus Rating Scale (UMRS) test panel was performed as part of 
the clinical patient evaluation. UMRS is a quantitative, 74-item clinical rating instrument 
comprising 8 sections (Frucht et al. 2002). The patients were video-recorded and evaluated 
by using the standard protocol. Higher UMRS scores indicate more severe myoclonus.  
Neuropsychological assessments were performed by an experienced neuropsychologist 
(M.Ä). General intellectual ability was assessed with the Wechsler Adult Intelligence Scale 
Revised (WAIS-R) (Wechsler D 1981), and verbal and performance Intelligence Quotients 
(VIQ, PIQ) were estimated.  
6.2.3 MR image acquisition 
The EPM1 patients and healthy control subjects underwent MRI of the brain (1.5 T, 
Siemens Magnetom Avanto, Erlangen, Germany) using a birdcage Tx/Rx head coil. T1-
weighted 3-dimensional images (MPRAGE, TR 1980 ms, TE 3.93 ms, flip angle 15°, matrix 
256 x 256, 176 sagittal slices, slice thickness 1.0 mm, in-slice resolution of 1.0 mm x 1.0 mm) 
were used for regional 3D TA. 
6.2.4 Texture analysis and volumes of interest definition 
TA was performed with the software package MaZda (MaZda 4.60 3D, Institute of 
Electronics, Technical University of Lodz, Poland) (Szczypinski et al. 2009, Hajek et al. 
2006) specially designed for texture analysis by Materka and co-workers as a part of the 
European COST B11 and the following COST B21 programs.  
Spherical volumes of interest (VOI) were manually placed bilaterally on each region of 
interest in the deep gray matter structures (thalamus, putamen, caudate nucleus, 
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hippocampus and amygdala; Figure 15). The VOIs were carefully placed to avoid any 
overlap with other anatomical structures or cerebrospinal fluid. The 3D VOI placement 
was done manually by two observers (S.S. and K.H.). 
Image gray level intensity normalization was performed with method limiting image 
intensities in the range [μ-3σ, μ+3σ], where μ is the mean gray level value and σ the 
standard deviation. This method has been shown to intensify differences between two 
classes when comparing image intensity normalization methods in texture classification 
(Collewet, Strzelecki & Mariette 2004).  
A total of 223 texture parameters were calculated based on the histogram, gradient, run-
length matrix and co-occurrence matrix (Table 13) (Szczypinski et al. 2009, Hajek et al. 
2006). Run-length matrix parameters were calculated in four directions: horizontal (0°), 
vertical (90°), 45° and 135°, and co-occurrence matrix parameters were calculated in three 
distances of 1, 2 and 3 voxels in each 3D spatial co-ordinate directions were considered. All 
of these texture features were calculated for each VOI. 
 
Table 13. Texture features used in the study. 
Histogram Absolute gradient Co-occurrence matrix Run-length matrix 
Mean Mean Angular second moment Run-length non-
uniformity 
Variance Variance Contrast Gray-level non-
uniformity 
Skewness Skewness Correlation Long run emphasis 
Kurtosis Kurtosis Sum of squares Short run emphasis 
Percentiles 1-, 10-, 50-, 
90-, 99-% 
Percentage of pixels 
with non-zero gradient 
Inverse difference 
moment 
Fraction image in runs 
  Sum average  
  Sum variance  
  Sum entropy  
  Difference variance  
  Difference entropy  
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Figure 15. Illustrative A) T1-weighted, B) T2-weighted and C) FLAIR images from a 34 year old 
male patient with EPM1. Mild frontoparietal cortical atrophy can be suspected but there are no 
visible focal abnormalities. 
 
6.2.5 Statistical analysis 
Statistical analyses were performed with SPSS 19.0 (IBM SPSS, Chicago, Illinois). P-values 
under 0.05 were considered statistically significant. Because of the small group size and 
skewed distributions, nonparametric statistical tests were used. The Mann-Whitney U test 
was used to evaluate the raw TA parameters to describe the textural difference between 
EPM1 patients and controls on each VOI. All 223 raw texture parameters were statistically 
tested to find out how many and which of the 223 parameters differed statistically.  
The texture parameters were calculated in several directions and pixel distances, mean 
value for different pixel distances, and directions were calculated for six texture 
parameters (Table 13) and for correlation analysis of four texture parameters (entropy, 
angular second moment, short run emphasis, long run emphasis). Thus, the Spearman 
correlation coefficient was used to assess any correlations between the mean values of the 
four texture parameters and the clinical parameters (myoclonus in action score, age, 
duration of the disease, PIQ and VIQ).  
To test the reproducibility of the TA, 10 control subjects were drawn by two observers. 
The intraclass correlation coefficient (ICC) with a 95% confidence interval, coefficient of 
variation (CV) and paired samples t-test were calculated. Co-occurrence parameters from 
one voxel distance (1, 0, 0) i.e., all together 1320 numerical values per observer were 
involved in the reproducibility analysis. 
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Table 14. Texture features that differed most between the patients with EPM1 and healthy 
controls. 
 Patient Control  
 Mean SD Mean SD p 
Histogram-based parameters      
      
Mean 3D      
VOI1, right thalamus 677.71 24.03 664.88 22.06 0.152 
VOI2, left thalamus 682.10 23.13 658.23 21.71 0.004 
VOI9, right putamen 631.92 21.25 653.66 24.70 0.016 
Variance 3D      
VOI1, right thalamus 1571.64 353.99 1148.05 204.36 0.001 
VOI2, left thalamus 1500.03 215.39 1113.45 160.68 0.000 
VOI9, right putamen 682.85 226.09 542.93 127.31 0.050 
      
Co-occurence-based parameters      
      
Mean of angular second moment      
VOI1, right thalamus 5.55 x10-4 1.42 x10-5 5.76 x10-4 1.52 x10-5 0.001 
VOI2, left thalamus 5.57 x10-4 1.05 x10-5 5.79 x10-4 1.21 x10-5 0.000 
VOI9, right putamen 9.06 x10-3 2.96 x10-4 9.38 x10-3 3.14 x10-4 0.006 
Mean of entropy      
VOI1, right thalamus 3.28 8.50 x10-3 3.27 8.61 x10-3 0.001 
VOI2, left thalamus 3.28 6.03 x10-3 3.27 6.93 x10-3 0.000 
VOI9, right putamen 2.11 1.04 x10-2 2.09 1.24 x10-2 0.005 
      
Run-length matrix-based parameters     
      
Mean of short run emphasis      
VOI1, right thalamus 9.91 x10-1 7.84 x10-4 9.90 x10-1 1.14 x10-3 0.000 
VOI2, left thalamus 9.91 x10-1 1.53 x10-3 9.90 x10-1 1.42 x10-3 0.042 
VOI9, right putamen 9.93 x10-1 2.46 x10-3 9.91 x10-1 3.30 x10-3 0.101 
Mean of long run emphasis      
VOI1, right thalamus 1.035 3.30 x10-3 1.042 4.63 x10-3 0.000 
VOI2, left thalamus 1.038 6.18 x10-3 1.043 5.72 x10-3 0.026 
VOI9, right putamen 1.029 1.02 x10-2 1.037 1.38 x10-2 0.109 
Run-length non-uniformity      
VOI1, right thalamus 1381.49 7.98 1372.74 13.29 0.046 
VOI2, left thalamus 1377.92 10.98 1369.90 17.78 0.050 
VOI9, right putamen 140.79 2.49 137.49 3.45 0.002 
Gray-level non-uniformity      
VOI1, right thalamus 11.41 1.00 12.95 1.21 0.001 
VOI2, left thalamus 11.48 0.70 13.14 0.99 0.000 
VOI9, right putamen 2.58 0.34 2.74 0.18 0.032 
Mean 3D and Variance 3D are single texture features whereas co-occurrence and run-length 
matrix-based parameters are the mean of each texture feature 
 
 
6.3 RESULTS 
The demographic and clinical data of patients with EPM1 are presented in Table 15. When 
assessed visually by experienced neuroradiologists (P.K. and R.V.), no focal signal 
intensity abnormalities were found (Figures 15 and 16).  
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Table 15. Demographic data of 16 EPM1 patients. 
 n Mean ± SD Range 
Sex, M/F 10/6   
Age, y  31.0 ± 10.9 18 − 51 
Age at EPM1 onset, y  9.6 ± 1.9 5 − 12 
Duration of disease, y  21.4 ± 10.2 8 − 41 
UMRS: Myoclonus with Action  49.1 ± 25.8 12 − 92 
Wheelchair use, no/occasionally/wheelchair bound 9/4/3   
Number of AED’s in use, 2/3/4/5 5/5/5/1   
Phenytoin use, never/earlier temporarily/unknown 9/6/1   
VIQ  82.4 ± 12.4  62 − 102 
PIQ  70.4 ± 13.1 52 − 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Volumes of interests and a three-dimensional view of the brain in MaZda. Image 
slices from a T1-weighted 3D image package illustrating the volumes of interest in a 19 year 
old female patient. There is no focal pathology or atrophy visible. VOIs are placed bilaterally in 
the thalamus, hippocampi, amygdalae, caudate nuclei and putamen. 
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6.3.1 Reproducibility 
Reproducibility of 3D TA proved to be excellent. There were no statistically significant 
differences (p=0.738) between Observer 1 and Observer 2 in the values of co-occurrence (1, 
0, 0) parameters. ICC was excellent (0.990). The CV was 1.90 for Observer 1, and 1.89 for 
Observer 2. 
6.3.2 Regional texture parameters differing between patients and control subjects 
The regional differences in texture parameters (n=223) were evaluated by the number of 
TA parameters with statistically significant differences between EPM1 patients and 
healthy controls (Table 16). The largest number of significant differences between EPM1 
patients and healthy controls were found in the VOIs of the thalamus (Table 16) and were 
based on co-occurrence matrix, in particular the following parameters: angular second 
moment, entropy, sum variance and sum average (Table 17). The values of entropy were 
higher in patients than in healthy controls whereas the angular second moment feature 
acted in the opposite direction (Table 14). 
The thalamus also differed in the histogram-based features including variance and 
mean as EPM1 patients had higher values than healthy controls. Furthermore, the run-
length matrix-based parameters also differed between patients and controls (Table 18). 
The values of short run emphasis were larger in patients than in healthy controls, whilst 
values of long run emphasis features acted in the opposite direction (Table 14). Values 
indicating gray-level non-uniformity were smaller in patients than in controls and vice 
versa with run-length non-uniformity (Table 14). 
In addition to the thalamus bilaterally, the right putamen provided statistically 
differing texture features between EPM1 patients and healthy controls (Tables 16 and 14). 
Again, significant differences were found in histogram-, co-occurrence matrix- and run-
length matrix-based parameters. No major differences were found between EPM1 patients 
and healthy controls in the left putamen, hippocampi, amygdalae or caudate nuclei. 
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Table 16. Volumes of interest (VOI) with number and percentages of statistically significantly 
different texture parameters from a total of 223 texture parameters between EPM1 patients 
and healthy controls. 
Region 
Volume of 
VOI (mm3) 
Number of statistically 
significant different 
parameters  
% 
VOI 1, Right side of the thalamus 1437 62 28% 
VOI 2, Left side of the thalamus 1437 83 37% 
VOI 3, Right central thalamus 66 27 12% 
VOI 4, Left central thalamus 66 12 5% 
VOI 5, Right amygdala 
144 
15 7% 
VOI 6, Left amygdala 
144 
11 5% 
VOI 7, Right hippocampus 144 4 0.5% 
VOI 8, Left hippocampus 144 11 5% 
VOI 9, Right putamen 
144 
59 26% 
VOI 10, Left putamen 
144 
10 1% 
VOI 11, Right caudate nucleus 144 7 3% 
VOI 12, Left caudate nucleus 144 16 7% 
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Table 17. The number of differing co-occurence based texture parameters (p<0.05) between 
EPM1 patients and healthy controls in the thalamus and putamen in three distances in all five 
evaluated directions (maximal number = 15 parameters). 
 Thalamus 
(right side) 
Thalamus 
(left side) 
Putamen 
right 
Putamen 
left 
Angular second moment 14/15 15/15 6/15 1/15 
Entropy 14/15 15/15 9/15 0/15 
Sum average 7/15 1/15 2/15 0/15 
Sum variance 1/15 8/15 0/15 0/15 
Sum entropy 3/15 3/15 5/15 0/15 
Sum of squares 4/15 0/15 4/15 1/15 
Contrast 1/15 6/15 1/15 1/15 
Correlation 1/15 6/15 0/15 0/15 
 
 
 
Table 18. The directions of differing run-length-based texture parameters (p<0.05) between 
EPM1 patients and healthy controls in the thalamus and putamen. 
 Thalamus 
(right side) 
Thalamus 
(left side) 
Putamen 
right 
Putamen 
left 
Long run emphasis Horizontal Horizontal 135° 45° 
 135° Vertical   
Short run emphasis Horizontal Vertical 135° 45° 
 135°    
Run-length non-uniformity 135° Horizontal Horizontal – 
  Vertical 45°  
   135°  
Gray-level non-uniformity All degrees All degrees All degrees – 
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6.3.3 Correlations between TA and clinical parameters 
The myoclonus in action score correlated significantly with the angular second moment 
values in the left side of the thalamus (VOI2, r=0.542, p=0.030) and tended to correlate with 
values from the right side of the thalamus (VOI1, r=0,440, p=0.088). A tendency for inverse 
correlation was observed between the myoclonus in action score and the entropy values 
both in the right side of the thalamus (r= -0.442, p=0.087) and left side of the thalamus (r= -
0.495, p=0.051). No correlations were found between the texture parameters in the 
thalamus and age, duration of the disorder, PIQ and VIQ. In the right putamen, the VIQ 
score significantly correlated with the entropy values (r= -0.498, p=0.050) and angular 
second moment values (r=0.514, p= 0.042). No correlations were found between the texture 
parameters in the right putamen and myoclonus in action score, age, duration of the 
disorder or PIQ. 
 
6.4 DISCUSSION 
 
The present study shows that MRI-based texture analysis reveals imperceptible alterations 
in EPM1 patients, especially in the thalamus. Three dimensional TA is a novel method for 
the analysis of MR images of the brain, and according to our results, 3D TA is able to 
provide subtle information of the structures of deep gray matter in EPM1 patients that 
could not be detected by direct visual inspection of the images. The TA changes were 
demonstrated by statistical analysis of the pixel gray level distributions in the volumes of 
interest in the anatomical structures analysed.  
In our study we used 3D texture analysis, a more advanced technique than reported in 
most of the previous TA studies (Castellano et al. 2004). Studies of TA in epilepsy are 
sparse but have evaluated hippocampal abnormalities in temporal lobe epilepsy ) (Yu et 
al. 2001, Bonilha et al. 2003, Jafari-Khouzani et al. 2010, Alegro et al. 2012) and observed 
subtle lesions of cortex in focal cortical dysplasia (Antel et al. 2003, Bernasconi et al. 2001). 
Recently, 2D texture analysis based on co-occurrence matrix was able to detect tissue 
alterations in the right side of the thalamus in JME, and both caudate nuclei and the 
thalamus in Machado-Joseph disease, a rare neurodegenerative disorder characterized by 
ataxia and motorical dysfunction (de Oliveira et al. 2013, de Oliveira et al. 2012) 
The present TA study detected significantly different thalamic texture features in EPM1 
patients compared to healthy controls. This is in line with imaging and experimental 
studies that have previously suggested thalamic and possible dopaminergic pathology in 
EPM1 (Koskenkorva et al. 2009, Mervaala et al. 1990, Mascalchi et al. 2002, Korja et al. 
2007b, Franceschetti et al. 2007, Tegelberg et al. 2012). The thalamus is a relay centre 
between subcortical areas and the cerebral cortex, and it has multiple sensory and motor 
functions, along with the regulation of awareness, attention, memory and language 
(Smythies 1997, Buchel et al. 1998, Johnson, Ojemann 2000). Lesions confined to the 
thalamus have been associated with asterixis (Lee, Marsden 1994), and hemorrhages 
restricted to the region lateralis of the thalamus lead to a cheiro-oral syndrome (Shintani, 
Tsuruoka & Shiigai 2000) or choreiform and dystonic movements associated with 
myorhythmia (Lera et al. 2000). Lesions of both thalamus and basal ganglia are related to 
dystonia (Lee et al. 1994). Similar clinical symptoms are seen in both EPM1 patients 
(Kälviäinen et al. 2008) and Cstb-deficient mice (Pennacchio et al. 1998) in the shape of 
ataxia, apraxia, dysarthia and involuntary asynchronous myoclonic jerks that occur 
mainly in the proximal muscles of the extremities. 
The most significantly different parameters in the thalami of EPM1 patients compared 
to controls were the second-order co-occurrence matrix-based parameters, especially 
angular second moment and entropy values. Angular second moment is a measure of  
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homogeneity as it measures the monotony of gray level transition in an image texture. The 
observed higher value of this feature in control individuals indicates that the intensity 
varies less in the VOI and the VOI is more homogenous than in EPM1 patients. Entropy 
indicates the complexity and randomness within the VOI. When the image is not 
texturally uniform then the value of entropy is larger (Haralick 1973). In other words, our 
results indicate that the thalamus may be structurally more complex and heterogenous in 
EPM1. 
We also observed differences in first-order histogram-based parameters and higher-
order RLM-based parameters. Histogram-based statistics assess the global distribution of 
pixels/voxels with specific gray level tones (Castellano et al. 2004). Several statistical 
properties can be calculated from the histogram. The mean is the average intensity level of 
the image, variance assesses the roughness of an image, skewness describes the histogram 
symmetry and kurtosis describes the flatness of the histogram. We found that EPM1 
patients had higher values of variance in the thalamus than those of the control group, 
thus the thalamic texture in EPM1 patients is rougher than that of healthy controls. 
RLM-based parameters assess the number of runs when two or more pixels/voxels have 
the same value in a present direction, and they describe the coarseness or smoothness of 
an image (Galloway 1975). Gray-level non-uniformity calculates how uniformly the runs 
are distributed among the gray levels; smaller values indicate that the distribution of runs 
is more uniform. The value of short run emphasis is larger in more coarse images and the 
value of long run emphasis is larger in smoother images. In the present study, the short 
run emphasis features were larger in the thalami of EPM1 patients than in healthy 
controls, indicating a more coarse thalamic texture. 
Put together, the observed differences in variance, angular second moment, entropy 
and short run emphasis features indicate that the texture of the thalamus may be more 
complex, rough and coarse in EPM1 patients than in healthy controls.  
The putamen together with the caudate nucleus and nucleus accumbens form the 
striatum, which is a major part of the basal ganglia. Basal ganglia are a part of the 
extrapyramidal motor system involved in cognition, emotion and motivation (Herrero, 
Barcia & Navarro 2002). The anterior parts of the striatum, including the putamen, are 
essential for learning, attention, planning (Graybiel 2005, Bellebaum et al. 2008) and verbal 
working memory (Dahlin et al. 2008), where dopamine plays an essential role in 
neurotransmission (Brooks 2006). Putamenal pathology is related to movement disorders 
that also contain cognitive features, for example Parkinson’s disease and Huntington’s 
disease (Turner, Desmurget 2010). Interestingly, microstructural and volumetric 
abnormalities of the putamen have also been observed in juvenile myoclonic epilepsy 
(Keller et al. 2011)which shares similar clinical characteristics with EPM1.  
Our results indicated that the right putamen had significantly different texture 
parameters in EPM1 patients when compared to the healthy controls. The most 
significantly different parameters were the same as those found in the thalamus 
bilaterally; co-occurrence matrix based angular second moment and entropy. The VIQ 
correlated negatively with entropy and positively with angular second moment values in 
the right putamen, indicating that the smaller the VIQ score, the more complex the texture 
in the right putamen. There was no correlation between myoclonus in action scores and 
entropy in the putamen of either hemisphere. Our VOI included the anterior, mainly 
rostrodorsal (associative) part of the putamen that is involved in learning new motor 
tasks, whereas the posterior caudoventral (sensorimotor) part of putamen is more 
involved in storage and execution of learned tasks (Jueptner et al. 1997, Lehericy et al. 
2005). The parallel textural alterations in the thalamus and right putamen are an 
interesting finding. Initially, basal ganglia-thalamocortical circuitry was considered to be 
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involved only in the control of movement but nowadays these structures are also regarded 
to be part of higher-order behavioral control (Herrero, Barcia & Navarro 2002, DeLong, 
Wichmann 2009). 
Memory problems are not main symptoms in EPM1 (Genton 2010, Magaudda et al. 
2006) and previous imaging studies have not revealed any hippocampal abnormalities. In 
agreement with the previous studies, we found no major textural differences in the 
hippocampi, amygdalae or caudate nuclei between the EPM1 patients and healthy 
controls.  
Our study has some limitations. The original study population had in part been 
scanned with slightly different MR imaging parameters. Since we wanted to make sure the 
different imaging parameters do not affect the TA results, our identical MRI data for TA 
remained relatively small. Further, some of the original patient imaging data could not be 
included in the texture analysis because of the suboptimal image quality caused by 
myoclonic movement artefacts. Finally, 16 patients and 16 controls from the original study 
population shared the identical imaging protocol and were included in the present TA 
study. The restrictions in the data collection reflect the fact that TA is still an experimental 
method with many limitations, including its potential sensitivity to slight differences in 
different scanners, coils and imaging protocols, complicating its routine clinical use and 
prohibiting data comparisons between institutions. 
To conclude, three dimensional TA proved to be a feasible method to obtain 
imperceptible quantitative individual information from MR images of the brain in EPM1. 
Patients with EPM1 exhibit more coarse and heterogeneous texture in thalamus and right 
putamen. The textural differences observed in the present study parallel the previous 
imaging, neuropathological, and molecular genetics studies of thalamic involvement in 
EPM1. Textural alterations in the right putamen is a novel finding. Our results indicate 
that the changes in both the thalamus and putamen may play an important role in the 
pathophysiology of EPM1. Further studies in larger patient materials will show whether 
3D TA could be a relevant tool for clinical applications. 
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7 General discussion 
 
EPM1 is a progressive neurodegenerative disorder with no specific cure. Although 
mutations in the CSTB gene are responsible for the primary defect in EPM1, the exact 
pathogenesis of the disorder remains unknown. Clinical research in EPM1 has been 
challenging due to small number of cases worldwide. Consequently, there are few 
imaging studies of EPM1 patients. In the present study, both the skeletal and cerebral 
abnormalities of EPM1 patients were assessed and combined to the clinical and 
neuropsychological data of the patients. 
 
7.1 SKELETAL FINDINGS IN EPM1 
Previously, three studies have documented bone findings in patients with EPM1. 
Koskiniemi et al. first described thickening of the skull and thoracic scoliosis in patients 
with in early 1970’s (Koskiniemi et al. 1974) when phenytoin was commonly used as a 
treatment in PMEs. A case report of a patient with two rare genetic disorders, both EPM1 
and myotonic dystrophy, exhibited thickening of the skull and with large frontal sinus in 
MRI but no focal pathology in the brain parenchyma (Nokelainen et al. 2000) similarly to 
the findings of EPM1 patients in the present study. Lately, thickening of the calvarium in 
four patients with EPM1 was interpreted as hyperostosis frontalis interna (HFI) (Korja et 
al. 2007a). In molecular genetic studies, CSTB and Cathepsin K have been shown to be 
interconnected in vitro leading to the altered osteoclast bone resorption activity (Laitala-
Leinonen et al. 2006). Reflecting to the previous studies, in the present study systematic 
analysis of head MRI and skeletal radiographs revealed more generalized skull thickening 
in EPM1 patients and scoliosis and an increased prevalence of abnormal skeletal findings 
that was not explained by the HFI, former phenytoin use, Paget’s disease or other 
conditions such as severe anaemia or hyperparathyroidism. Both scoliosis and accessory 
ossicles were common and the prevalences were higher than given in literature (Carter, 
Haynes 1987, Hong et al. 2010, Ueno et al. 2011, Mellado et al. 2003). Taken together, 
skeletal findings suggest that abnormal ossification of the skeleton is a universal feature of 
EPM1 which may be associated with a defect in CSTB function.  
 
7.2 REGIONAL CORTICAL THINNING AND COGNITION IN EPM1 
As previously shown, the compound heterozygous individuals exhibit a more severe 
form of the disorder (Koskenkorva et al. 2011, Canafoglia et al. 2012). However, most of 
the patients with EPM1 are homozygous. In spite of uniform genotype, the severity of the 
symptoms, myoclonus and neurocognitive function is variable among patients with 
EPM1. 
By combining the neuropsychological data with CTH in homozygous patients with 
EPM1, we found that the patients with a more severe form of the disease had thinner 
cortex compared to them with a milder form of the disease. The anatomical areas 
responsible for processing of verbal and complex visual data, and areas responsible for 
higher-order cognitive functions were affected. Parallel cortical thinning has been 
observed in mice already at a young age (Tegelberg et al. 2012). Furthermore, in mice 
cortical atrophy precedes the loss of neurons in corresponding thalamic relay nucleus.  
Previous studies have shown that sensorimotor cortex is affected in patients with EPM1 
compared to the healthy controls (Koskenkorva et al. 2009, Koskenkorva et al. 2012). The 
severity of myoclonus was used as a criterion for different subgroups in the present CTH 
study as well. The most interesting finding in CTH was that although the myoclonus and 
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motor dysfunction is a peculiar character in EPM1, there were no major differences in 
sensorimotor cortical areas between the three severity sub-groups. Thus, it can be 
suggested that the sensorimotor cortices are simirlarly damaged in EPM1. Whereas, the 
subtle changes in more limited cortical areas result in the heterogeneity of the cognitive 
function and severity in symptoms in patients with EPM1. 
The verbal memory has been found to be the least affected cognitive domain in Finnish 
patients with EPM1 (unpublished data). No correlations were found between the verbal 
memory scores and CTH as well as no major textural differences in hippocampi between 
the EPM1 patients and healthy controls in TA study. This is similar to the previous 
imaging studies and that the memory problems are not the main symptoms in EPM1 
(Genton 2010, Magaudda et al. 2006). 
 
7.3 SUBTLE TEXTURAL ALTERATIONS IN EPM1 
TA detected significant differing texture features especially in the thalamus of EPM1 
patients compared to the healthy controls. Also right putamen was significantly affected 
that is a novel finding. Thalamus is a relay center between subcortical areas and the 
cerebral cortex, and it has multiple functions both in sensory and motor aspects, along 
with the regulation of awareness, attention, memory and language (Smythies 1997, Buchel 
et al. 1998, Johnson, Ojemann 2000). Both the myoclonus, mice studies and previous 
imaging finding in patients with EPM1 support the role of the thalamus in the 
pathophysiology of EPM1 (Koskenkorva et al. 2009, Mascalchi et al. 2002, Korja et al. 
2007b, Korja et al. 2010, Manninen et al. 2013, Franceschetti et al. 2007, Tegelberg et al. 
2012). Thalamus is a fascinating part of the brain in regards to EPM1, and possible 
dopaminergic defect in thalamus should be further studied. As previously proposed 
dopamine may have a role in the pathophysiology of EPM1 (Mervaala et al. 1990, Korja et 
al. 2007b).  
In addition, the TA study demonstrates that three dimensional TA is a feasible method 
to obtain imperceptible quantitative information from MR images of the brain. However, 
there were also some limitations including slightly different MR imaging parameters and 
artefacts due the suboptimal image quality caused by the myoclonic movement artefact. 
The restrictions in the data collection reflect the fact that TA is still an experimental 
method with many limitations. This includes its potential sensitivity to slight differences 
in different scanners, coils and imaging protocols complicating its routine clinical use and 
prohibiting data comparisons between institutions. However, TA is already applied in 
different fields of industry and this study further demonstrates that it can be applied in 
MRI as well. Further studies in larger patient materials will show its potential in clinical 
imaging. 
Thus far, it has been shown that patients with EPM1 have widespread alterations both 
in cortical and subcortical areas not limited only to the motor areas. The human brain is 
complex and there are still many mysteries to investigate. Seldomly, one area of the brain 
is purely involved in a motor, sensory or cognitive system but these all functions are 
layered and transposed into the greater whole. More commonly, damages are not 
restricted to the certain areas of the brain. In other words, all these aspects are united 
which create every patient’s individual symptoms. Today, when individual treatments are 
increasingly topical issues, it would be essential to use tailored medication by the 
distinctive characteristics of the patients. For example, to be able to predict the progression 
of the disease. Modern image analysis can be one tool in this characterization along with 
genetic testing and other biomarkers. 
To conclude, as seen in EPM1, the evaluation of human brain in current routine MR 
images is not sufficient to show subtle changes of the brain. Still more data is needed 
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about the normal age- and sex-related changes and effects of genetic factors on brain. 
Future research may support the development of more automated MR image analysis 
methods to evaluate patients’ brain individually, and could be applied in routine clinical 
practice. 
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8 Conclusions 
 
I Patients with EPM1 had thickening of the skull and an increased prevalence of 
abnormal findings in skeletal radiographs. Skeletal findings in EPM1 are 
suggested to be connected to defective cystatin B function.  
 
 
II Patients with a more severe form of the disorder exhibit more widespread 
cortical thinning compared to the patients with milder form of the disease. 
Areas involved in higher-order cognitive function were particularly affected 
providing a structural neuroanatomical-biological basis for disease severity 
and cognitive decline in EPM1. 
 
 
III TA detected subtle textural changes in EPM1 patients especially in thalamus 
and right putamen. TA has potential in MR image analysis while still being an 
experimental method with its limitations recognized in this study. 
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